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Abstract 
Glioblastoma multiforme (GBM) is a deadly grade IV brain tumor 
characterized by a heterogeneous population of cells that are drug resistant, 
aggressive, and infiltrative. The current standard of care, which has not changed 
in over a decade, only provides GBM patients with 12-14 months survival post 
diagnosis. We asked if the addition of a novel endoplasmic reticulum (ER) stress 
inducing agent, JLK1486, to the standard chemotherapy, temozolomide (TMZ), 
which induces DNA double strand breaks (DSBs), would enhance TMZ’s 
efficacy. Because GBMs rely on the ER to mitigate their hypoxic environment 
and DNA repair to fix TMZ induced DSBs, we reasoned that DSBs occurring 
during heightened ER stress would be deleterious. 
Treatment of GBM cells with TMZ+JLK1486 decreased cell viability and 
increased cell death due to apoptosis.  We found that TMZ+JLK1486 prolonged 
ER stress induction, as indicated by elevated ER stress marker BiP, ATF4, and 
CHOP, while sustaining activation of the DNA damage response pathway.  This 
combination produced unresolved DNA DSBs due to RAD51 reduction, a key 
DNA repair factor. The combination of TMZ+JLK1486 is a potential novel 
therapeutic combination and suggests an inverse relationship between ER stress 
and DNA repair pathways. 
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"CHAPTER I 
Introduction to Glioblastoma Multiforme  
Overview and rationale  
Glioblastoma Multiforme (GBM) is a deadly grade IV brain tumor 
characterized by a heterogeneous population of cells forming a 
chemotherapeutic resistant, highly aggressive, and infiltrative tumor [1]. The 
development of comparative genomic hybridization (CGH) coupled with cDNA 
microarray analysis, fluorescent in situ hybridization (FISH), and completion of 
the cancer genome atlas (TCGA) has done much to identify and increase the 
understanding of mutations leading to GBM development and progression [2-4]. 
This knowledge will, hopefully, culminate in the development of effective, 
targeted therapies. At this time, the best treatment available for GBM patients is 
comprised of surgical resection, radiation therapy (RT) and the chemotherapeutic 
agent temozolomide (TMZ) [1] [5]. This provides GBM patients with a 12 to 14 
months survival period post diagnosis, with only 6.9 months between treatment 
completion and tumor relapse [5]. This leaves much room for improvement.  
Combination therapies are an attractive therapeutic approach as two 
pathways, critical for survival, can be inhibited. This may lead to decreased 
viability and delay tumor recurrence in patients. GBMs are solid tumors with 
viable cells maintained in extreme regions of hypoxia with decreased access to 
nutrients and glucose  [6-9]. Such an unfavorable environment should activate 
the endoplasmic reticulum (ER) stress response pathway, resulting in cell death 
#[10]. However, glioma cells increase expression of pro-survival ER factors, 
turning this homeostasis mechanism into one that promotes cancer cell survival 
[11-15].  In addition to thriving in a state of chronic stress, glioma cells must 
prevent their highly unstable genomes from triggering apoptosis during 
replication. To circumvent this, GBMs increase the expression of DNA repair 
factors to promote homologous recombination (HR) [16-18]. The repair of 
deleterious DNA double strand breaks (DSB) keeps their fragile, aberrant 
genomes intact, supporting their viability.   
Manipulating these pathways may exacerbate the fine balance of surviving 
ER stress and genomic instability, pushing the cell towards death.  The work 
presented in this dissertation explores the combination of a DNA alkylating agent 
(TMZ) with a novel ER stress-inducing drug, JLK1486. We reasoned that 
induction of prolonged ER stress in the presence of increased DNA damage 
would be catastrophic. This work found that JLK1486 increased the efficacy of 
TMZ, resulting in decreased viability due to apoptosis [19]. Induction of apoptosis 
was the result of prolonged, unresolved ER stress promoting unrepaired DNA 
DSBs due to reduction of the key DNA HR factor, RADiation sensitive 51 
(RAD51) [19].  To understand why the combination is detrimental to cells, we will 
address two themes: DNA repair and the ER stress response pathway. 
WHO Classification of astrocytomas   
The World Health Organization (WHO) categorizes astrocytomas into four 
grades, grade I being the least aggressive and grade IV the most [3]. 
$Accumulation of genetic alterations drives grade progression and tumor 
aggressiveness [3].  
Pilocytic astrocytomas, grade I brain tumors, are benign masses with slow 
growing, well-differentiated cells [20]. These tumors rarely progress and are 
considered curable as they can be surgically removed [20]. 
Astrocytomas, grade II brain tumors, are comprised of highly proliferative 
and infiltrative cells [21]. Because these cells infiltrate into normal brain, complete 
surgical resection is nearly impossible. One of the first genetic alterations 
associated with grade II are P53 mutations [20-21].  Mutations, usually in exons 
5, 7 or 8, result in either missense or frameshifts that inactivate P53’s DNA 
binding domain [21]. As P53 has been implicated in the regulation of over 2,500 
genes, it is easy to understand how its loss would impact cell integrity  [4]. The 
best-characterized target of P53, P21, is a cyclin dependent kinase (CDK) 
inhibitor responsible for initiating and maintaining a G1 to S cell cycle arrest [4] 
[21]. Therefore, P53 mutations result in loss of cell cycle arrest and increased 
proliferation due to decreased P21 transcription. In addition to P53 mutations, 
30% of astrocytomas present with loss of heterozygosity (LOH) of chromosome 
22q, the coding region for a pro-apoptotic member of the Bcl-2 family [3]. P53 
and 22q LOH are early events that initiate astrocytoma development by 
generating a population of highly proliferative and apoptosis resistant glioma 
cells. These genetic alterations facilitate grade II to grade III progression. 
%Anaplastic astrocytomas, grade III tumors, contain grade II genetic 
alterations as well as LOH of 19q and deletion of tumor suppressor genes 
(TSGs) found on chromosomes 9p (P16), 11p,13q (retinoblastoma;RB), and 19q 
[20, 21]. Loss of P16 promotes CDK4/Cyclin D1 complex formation and kinase 
activity, resulting in phosphorylation of RB [21].  Phosphorylated RB is unable to 
bind E2F transcription factors, resulting in increased expression of G1 to S cell 
cycle progression factors. As P16 and RB function as cell cycle brakes, their loss 
allows aberrant cells to cycle.  
Glioblastomas, grade IV brain tumors, are divided into two categories, 
progressive (secondary tumors) or de-novo (primary tumors) [22]. Progressive 
tumors are derived from lower grade astrocytomas, grade II and III, accumulating 
additional mutations over a 5-10 year span, leading to grade IV tumors [4] [20]. 
Conversely, de novo GBM patients lack clinical or histopathological evidence of a 
preceding tumor [1] [20]. Two characteristics distinguish de novo GBMs from 
secondary GBMs. First, 67% of secondary tumors contain P53 mutations in 
comparison to only 11% of de novo tumors, suggesting secondary GBMs depend 
on P53 mutations to promote tumorigenicity and progression [20].  Second, 40 to 
63% of de novo tumors present with LOH of chromosome 10, resulting in loss of 
the phosphatase and tensin homolog (PTEN) TSG [1] [20] [22]. As secondary 
GBM tumors are less common than de novo ones, the genetic alterations that 
contribute to de novo GBM proliferation, angiogenesis, invasion, and apoptotic 
&resistance will be examined [1] [20]. Understanding these pathways leads to the 
development of smarter combination therapies for GBM patients. 
Clinical and pathological presentations of GBMs   
GBM patients initially present with symptoms of headache, memory loss, 
confusion, seizure, and changes in personality [1]. De novo GBMs are diagnosed 
in patients 50 years of age and older and are 40% more common in men than 
women [1]. MRIs indicate a brain mass associated with edema and central 
regions of necrosis surrounded by areas of hypoxia [1] [21]. These regions are 
comprised of proliferating glioma cells as well as endothelial cells [4].  As these 
tumors are highly infiltrative, surgeons must balance obtaining clean margins with 
quality of life after surgery [1] [21] [23]. 
De novo GBM genetic alterations: losses, translocations, and 
amplifications  
CGH, FISH, and direct sequencing of grade IV GBMs identified large 
numbers of chromosomal aberrations [2,3]. CGH studies suggest GBMs have at 
least fourteen genomic amplifications and seventeen or more genomic losses 
and deletions that drive GBM development [2,4].  
Loss of chromosomes 1, 10, 11, 13, 17, 19 and 22 are common and often 
associated with mutations in the CDKN2 and PTEN TSGs [2]. Correlation studies 
suggest loss of 1p occurs with loss of 19q, while gain of chromosome 7 occurs 
with loss of chromosome 10, and loss of chromosome 10 occurs with loss of 19q 
[2,3]. Gain of 8q was found to occur with loss of 9p while co-amplification of 3p 
'and 12p was correlated with loss of chromosomes 10 and 20 [3].  Recently, five 
novel regions containing TSGs including TOPR5, FANCG, and TP53BP1, were 
found to be deleted in GBMs [3]. This clearly illustrates how genome losses and 
amplifications result in a heterogeneously unstable genome. This unstable 
genome might be therapeutically exploited as inhibition of DNA repair factors 
may prevent glioma cells from maintaining their aberrant chromosomes. 
In 2008, the Cancer Genome Atlas sequenced over 200 human GBMs, 
isolating candidate cancer genes as well as analyzing methylation status, DNA 
copy number variation, and non-coding RNAs in GBMs. This work suggests that 
mutations in cell cycle regulators and receptor tyrosine kinase pathways are key 
to GBM development  [24]. 
PI3K / PTEN / AKT axis  
 Ablation of PTEN, occurring in 40-63% of GBM patients, is due to LOH of 
chromosome 10 [1] [20] [22]. This is problematic as PTEN negatively regulates 
receptor tyrosine kinases (RTKs) pathways that promote survival [4]. PTEN loss 
results in mitogen-activated phosphoinositide-3-kinases (PI3Ks) generating 
anionic phospholipids that turn on downstream survival kinase pathways, such as 
AKT [4].  AKT promotes cell cycle progression by sequestering the FOXO 
transcription factor in the cytoplasm, preventing transcription of p21, resulting in 
increased CDK/cyclin E complex formation and loss of G1 cell cycle arrest [4].  In 
addition to increasing RTK activity, PTEN loss decreases chromosomal stability, 
as it has been shown to bind to chromosome centromeres and facilitate DNA 
(repair [4].  As PTEN regulates processes ranging from cell division to DNA 
repair, it is easy to see how loss of this TSG impacts several pathways, resulting 
in genomic and cellular aberrations. 
Epidermal Growth Factor Receptor amplification 
 The epidermal growth factor receptor (EGFR), a RTK that promotes 
proliferation and inhibits apoptosis, is amplified in 35 to 63% of de novo grade IV 
tumors [1] [4] [20] [22]. Amplification results in increased mRNA levels as well as 
protein levels [22].  Fifty percent of patients with amplified EGFR have deletions 
in exons 2-7, resulting in a constitutively active receptor due to partial loss of the 
extracellular binding domain [1]. This variant, VIII, increases proliferation and 
decreases apoptosis in comparison to full length amplified EGFR [4]. 
 EGFR amplification and the VIII variant transmit cyto-protective measures 
through the PI3K/AKT and RAS/RAF/MEK/ERK signaling cascade [25]. VIII in 
particular leads to increased repair of DNA double strand breaks (DSBs) by 
increasing activation of DNA damage response (DDR) factors, including ataxia 
telangiectasia-mutated kinase (ATM) and RADiation sensitive 51 (RAD51) [25].  
EGFR and MEK inhibitors decrease ATM and RAD51 mediated repair of DNA 
DSBs, increasing genomic instability, resulting in decreased viability [25]. 
Manipulation of DNA repair factors, in particular RAD51, may be a means to 
sensitize cells that have exploited RTK pathways to maintain their highly unstable 
genomes. 
) The VIII variant also promotes vasculature development in vivo [26]. Mice 
injected with VIII-expressing glioma cells versus amplified full length EGFR 
resulted in faster and larger tumor formation with increased vascular proliferation. 
This was due to increased expression and secretion of interluekin-6 (IL-6) 
elevating expression of vascular endothelial growth factor (VEGF), which induces 
the proliferation of endothelial cells [26].  Thus, targeting of the EGFR pathway 
may not only sensitize cells by preventing the repair of DNA DSBs, but may also 
decrease tumor vasculature, also decreasing tumor cell viability. 
Increased expression of the Platelet Derived Growth Factor Receptor 
 In addition to EGFR over-expression, grade IV tumors also present with 
increased expression of the platelet derived growth factor receptor (PDGFR)[1] 
[3,4]. Increased expression of the receptor coincides with increased expression 
of PDGF alpha and beta-activating ligands, creating an autocrine loop [1] [4]. 
PDGFR activation promotes and supports glioma proliferation while inhibiting 
apoptosis by also signaling through the PI3K-AKT-mTOR pathways, again 
highlighting how loss of PTEN promotes tumorigenicity [1] [4]. 
Loss of cell cycle regulation  
 Although aberrant activation of RTKs promotes cell cycle entry and 
progression, the highly aberrant genome of glioma cells should trigger cell cycle 
arrest, leading to apoptosis. To prevent this, grade IV tumors use LOH of P16, 
resulting in loss of RB mediated G1 arrest, to allow S phase entry despite 
unrepaired single strand breaks, crosslinks, or mismatches [4]. Additionally, 15% 
*of grade IV tumors have amplified CDK4, circumventing wild type RB negative 
regulation of CDK transcription [2] [4]. 
Resistance to apoptosis 
 Increased resistance to apoptosis is primarily due to loss of PTEN’s 
negative regulation of the PI3K / AKT signaling axis [4]. However, GBMs have 
evolved two additional mechanisms to evade apoptosis. First, to avoid extrinsic 
cell death mediated by TRAIL binding to death receptors 4 and/or 5 (DR4, DR5), 
glioma cells express death decoy receptors (DDcR) [4]. These DDcRs act as 
antagonistic receptors, preventing TRAIL from binding and initiating cell death 
through caspase effectors downstream of DR5.  Secondly, glioma cells escape 
intrinsic mediated apoptosis by up-regulating the expression of Bcl-2 anti-
apoptotic members, such as BAK, BAD, BID, BAX, and BCL-XL [4]. This shifts 
the ratio in favor of Bcl-2 pro-survival factors, preventing activity of pro-apoptotic 
Bcl-2 member from promoting mitochondrial mediated apoptosis through release 
of cytochrome C and cleavage of effector caspase 3. For example, the EGFR VIII 
mutation up-regulates Bcl-XL expression, correlating with chemotherapeutic 
resistance to and prevention of cell death caused by cross-linking agents such as 
cisplatin [4]. 
 Solid tumors are at high risk of hypoxia-induced death. Normal brain 
oxygen levels range from 0.5 to 7%; however, 42% of gliomas present with 
severe hypoxia, defined as regions with oxygen levels less than 0.1% [9]. This is 
due to rapidly proliferating cells moving beyond the area oxygen can diffuse from 
"+
blood vessels. To alleviate this, glioma cells express high levels of angiogenic 
factors, such as VEGF, angiopietin 2, and PDGF [4] [8].  Although this promotes 
blood vessel formation, the resulting network is highly aberrant due to 
hyperplastic endothelial cells forming twisted, non-connected, and dead-end 
junctions [1] [4] [9]. In addition to malformed vessels, endothelial cells within the 
vessels do not form tight junctions, resulting in leaky, inefficient delivery. As 
pressure builds within the tortuous vessels, they often hemorrhage. Instead of 
promoting blood flow, the suboptimal network exacerbates hypoxic conditions as 
it is unable to efficiently deliver oxygen and nutrients to rapidly proliferating cells 
[4].  This results in necrosis, a pathological hallmark of GBMs [4] [8].  
Although hypoxia-induced necrosis is lethal to some glioma cells, it 
promotes tumorigenicity by forming a population of chemotherapeutic and 
radiation resistant cells [4]. Radiation is only effective when oxygen generates 
free radicals to react with DNA, forming single and double stranded breaks. If 
oxygen levels are low, the formation of damaging free radicals is greatly reduced 
[69].  Additionally, abnormal blood vessel development impedes 
chemotherapeutics delivery, increasing resistance. Therefore, hypoxia selects 
cells capable of surviving and proliferating in an adverse environment, creating a 
sub-population of cells with increased tumorigenicity. 
In addition to promoting chemo and radiation resistance, hypoxia 
promotes invasion, providing a mechanism for cells to exit unfavorable 
environments. For instance, GBMs increase expression of metalloproteases 
""
(MMP) 2 and 9 that correlate with an invasive phenotype in response to hypoxia 
[4] [27]. Additionally, increased expression of cysteine proteases, in particular 
cathepsin beta, aids invasion by degrading the extracellular matrix (ECM) [4] 
[28].  
The myriad of genetic alterations promoting proliferation, survival, 
angiogenesis, and apoptotic resistance generates a highly aggressive tumor that 
is difficult to treat. Although the fundamental genetic changes driving GBM 
progression and development have been identified, they have not yet translated 
into effective clinical treatments, leaving clinicians with three basic tools to treat 
GBM patients. 
Treatment: surgical resection, radiation, and temozolomide  
 The majority of GBM patients undergo surgical debulking before radiation 
therapy [1]. However, surgical resection is limited by tumor location and 
infiltration [1] [5]. GBM patients receive fractionated RT every five days over a 
six-week time course, resulting in a total of 60 Gy. Addition of RT to surgery 
increases survival from 3-4 months to 7-12.1 months [1] [5]. The addition of 
nitrosourea chemotherapies, such as carmustine, only gave a 5% increase in 
survival, leading many to question their clinical use [5]. It was not until 2005 when 
Stupp et al published their landmark study reporting the combination of RT with 
temozolomide that significant treatment progress was made. 
 Temozolomide (TMZ) is an oral alkylating agent that efficiently crosses the 
blood brain barrier (BBB) [29, 30].  It breaks down to form the reactive 
"#
intermediate MTIC, which degrades to a methyldiazonium cation, resulting in 
alkylation of N7 guanine (70%), N3 adenine residues (9.2%), and O6 guanine 
residues (5%) [29]. The N7 and N3 adducts are not deleterious as either base 
excision repair (BER) or nucleotide excision repair (NER) recognizes and 
removes these methyl groups [29]. However, neither NER nor BER recognize 
and excise O6 alkylated guanine residues. Because the methyl group changes 
guanine’s shape, the only base it can pair with during replication is thymine. A G-
T pairing activates the mismatch repair response (MMR), resulting in excision of 
the thymine [29] [31]. However, as long as the O6 residue remains alkylated, the 
only base DNA polymerase can insert is thymine, resulting in futile cycles of 
MMR. To prevent replication fork collapse, the polymerase passes over the 
alkylated O6 guanine, generating a single strand break.  The single strand break 
is converted to a double strand break during the next round of replication [32]. If 
these DSBs are not repaired, G2/M arrest occurs, resulting in apoptosis [29] [33]. 
The addition of TMZ to RT increased survival from 7-12.1 months to 14.6 
months with the combination [5]. As a result of this study, the standard of care for 
GBM patients is surgery followed by RT with concomitant and adjuvant TMZ. A 
two-year follow up study of patients who received RT had a 10.9% survival while 
those who received RT+TMZ had a 27.2% survival. This trend continued to three 
(4.4% versus 12.1%), four (3.0% versus 9.8%), and five-year survival rates (1.9% 
versus 10.9%), with TMZ+RT patients consistently presenting at higher survival 
rates [34]. As exciting and encouraging as these 2005 results were, this 
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therapeutic triad has not changed or improved in over a decade. Furthermore, it 
is incapable of preventing tumor recurrence. After completing RT+TMZ, patient’s 
tumors usually recur within 6.9 months [1]. Of these recurrent tumors, only 5.4% 
are sensitive to TMZ, and surgical debulking is limited by the preceding debulking 
[1]. There is a great need to improve time to recurrence and patient survival.  To 
address this, we explored the use of a novel ER stress-inducing agent, JLK1486, 
with TMZ, to determine if this combination would decrease cell viability and delay 
recurrence.  
Introduction to JLK1486  
 JLK1486, a bis-8-hydroxyquinoline substituted benzylamine (HQ motif), 
was synthesized with 15 other HQ analogs as potential cytotoxic agents to be 
used in a forward based chemical screen [35]. Of the 16 HQ motifs synthesized, 
seven exhibited levels of cytotoxicity in the KB3-1 human mouth epidermal 
cancer cell line [35]. Two of the seven HQ motifs, JLK1486 and JLK1472, had 
CC50’s in the nanomolar range, leading to further study [35]. Initial 
characterization in the laboratory of Dr. Jean Louis Kraus (JLK), demonstrated 
that JLK1486 did not inhibit proteosome activity, but was capable of increasing 
caspase 3 and 7 activity [35]. This made it an attractive candidate to study as it 
suggested the drug was capable of initiating apoptosis. 
Bis-8-hydroxyquinolines are highly reactive and fragment to form quinine 
methide (QM) reactive species [36]. JLK1486 QM species are not electrophilic 
enough to react with DNA, instead, they preferentially alkylate thiol residues [36, 
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[37]. JLK1486 alkylation of thiol residues blocks the formation of disulfide bonds 
required for protein tertiary structure [37[38].  This would lead to the 
accumulation of unfolded proteins in the endoplasmic reticulum (ER), triggering 
ER stress and subsequent activation of the unfolded protein response (UPR) [10] 
[39]. Microarray analysis of JLK1486 treated glioma cells, U87, confirmed this as 
ER stress response genes increased in response to JLK1486 treatment [36]. 
DNA damage and ER stress pathways crosstalk  
 Recent data suggests that sustained ER stress inhibits repair of DNA 
DSBs, resulting in decreased viability due to unrepaired DNA damage. Treatment 
of human lung cancer cells with the ER stress inducing agent tunicamycin leads 
to decreased expression of RAD51, a key DNA repair factor that promotes HR, 
resulting in unresolved DNA DSBs [40]. Hypoxia, a trigger of ER stress, was also 
shown to decrease RAD51 protein levels in breast cancer cell lines, leading to 
decreased viability [41]. Additionally, treatment of breast cancer cells with a 
PERK inhibitor, preventing activation of this ER kinase receptor, results in 
decreased DNA repair and increased sensitivity to RT [42]. Treatment of glioma 
cells with the 17AAG heat shock protein 90 (HSP90) inhibitor, prevented 
molecular chaperones from binding to and refolding unfolded proteins, and 
decreased RAD51 and BRAC2 protein levels, resulting in decreased HR [43].  
The combination of 17AAG with a PARP inhibitor followed by RT further 
exacerbated DNA damage by preventing repair of single stranded breaks and 
double strand DNA breaks, decreasing proliferation and clonogenic survival [43].  
"&
During ER stress, unfolded and misfolded proteins within the ER are 
targeted for proteasomal-mediated degradation. Proteasomal inhibition triggers 
apoptosis as cells are unable to clear aberrant proteins. Treatment of glioma 
cells with bortezimib (Velcade ™), a proteosomal inhibitor, increases sensitivity 
to TRAIL mediated apoptosis [44]. Combination of Velcade™,  with vorinostat, a 
histone deacetylase inhibitor, in glioma cells, decreases RAD51 protein, resulting 
in unresolved DNA DSBs [44]. Non small cell lung cancer cells treated with 
Velcade™, and exposed to RT underwent an 80-90% reduction in HR due to 
significant decreases in DNA repair factors FANCD2 and RAD51 [45]. 
These studies suggest inability to resolve ER stress results in delayed 
repair of DNA DSBs due to decreased HR. Although the exact mechanism is 
unknown, it is possible that sustained phosphorylation of eIF2 alpha leads to 
decreased translation of these HR factors.  As TMZ alkylates DNA, resulting in 
the generation of DNA double strand breaks, and JLK1486 inhibits the formation 
of disulfide bonds, triggering ER stress, we reasoned that the combination of 
these two drugs would decrease GBM viability.  
Summary  
GBMs are genetically heterogeneous grade IV brain tumors [1]. Deletions, 
translocations, inversions, and amplifications promote glioma cell survival in 
adverse environments through receptor tyrosine kinase activation [2, 3] [24]. 
Furthermore, glioma cells alleviate hypoxia by increasing expression of 
angiogenic factors that promote blood vessel formation [8] [46,[46].  Although 
"'
these genetic alterations and adaptations serve as survival mechanisms, they 
can be therapeutically exploited. Because of their genetic aberrancies, gliomas 
heavily rely on their DNA damage repair response to maintain their genome while 
commandeering the ER stress response pathway to promote survival in highly 
unfavorable environments [39] [47]. We will focus on understanding how 
interference with DNA repair, specifically RAD51, and exacerbation of ER stress 
sensitizes GBM cells to the combination of TMZ and JLK1486. 
Introduction to the DNA damage response pathway  
Rationale  
TMZ induces the formation of DNA DSBs [29]. These breaks must be repaired in 
order for the cell to avoid cell cycle arrest and / or apoptosis [33]. To do so, DNA 
damage response and repair factors must be activated, in particular ATM, CHK2, 
and RAD51 [48]. Understanding how these factors promote survival and why 
their inhibition is detrimental to cells provides the basis for the TMZ+JLK1486 
combination treatment. 
Overview of DNA damage repair: function, response, and key players  
The DNA damage response (DDR) is the integrated network responsible 
for preventing genetically unstable cells from replicating [50, [49]. It maintains the 
genetic integrity of the organism, promoting homeostasis by reducing the risk of 
cellular transformation that leads to cancer development [50, 51]. 
The DDR is activated in response to a myriad of lesions, including inter 
and intra strand crosslinks, base pair mismatches, and DNA single strand (SSBs) 
"(
and DSBs [50].  Depending on the type of damage, the DDR activates specific 
pathways to recruit factors to the site of damage to mediate repair. For instance, 
the mismatch repair pathway (MMR) recognizes and removes mismatched bases 
while the nucleotide excision repair pathway (NER) detects and excises bulky 
DNA lesions [52]. Of the vast number of DNA lesions, the most deleterious are 
DNA DSBs arising from stalled replication forks, oxidative damage, or 
chemotherapeutic agents [33] [51]. DNA DSBs promote genetic instability 
through genomic and oncogenic translocations, inversions, and deletions, 
triggering mitotic catastrophe and cell death [17] [52]. This is of particular interest 
as temozolomide induces the formation of DSBs.  
The cell utilizes two mechanisms to resolve DNA DSBs, non-homologous 
end joining (NHEJ) and homologous recombination (HR) [52]. NHEJ is 
traditionally viewed as an error-prone repair system in which two free DNA ends 
are simply ligated together [54]. Although this efficiently repairs the break, it 
results in loss of genetic material and translocations if two different chromosomes 
are fused together. Conversely, HR preserves genetic material and stability by 
using the sister chromatid of the damaged chromosome as a template to repair 
the DSB [54]. 
Signaling pathways activated by DDR converge to prevent damaged cells 
from propagating. Activation of cell cycle checkpoint kinases 1 and 2 (CHK1, 
CHK2) initiate either a G1/S or G2/M arrest, preventing damaged cells from 
replicating or undergoing mitosis [50] [52] [53]. This stall allows DNA repair 
")
factors to localize to DNA DSBs and initiate HR, giving the cell time to repair 
damage. However, if the damage is not repaired, the cell is at risk of either 
entering a state of senescence or undergoing apoptosis. This clears the aberrant 
cell from the system, protecting the organism and promoting tissue homeostasis 
[50] [52] [55]. Cancer cells, GBM’s in particular, hijack the DDR to promote 
survival despite severe genetic instability by increasing factors that mediate HR, 
allowing them to survive and proliferate despite stringent chemotherapeutic 
regimens [16] [17] [54] . 
Detection of DNA DSBs: sensors, transducers, and effectors  
Before catastrophic DNA DSBs can be repaired, the cell must detect 
them. DSBs activate the DDR sensors and alert the cell to the damage. Although 
poly-ADP-ribose polymerase (PARP) and the Mre11-RAD50-Nbs1 (MRN) 
complex are thought to be the primary initial sensors, a plethora of other DNA 
repair proteins can also fill this role  [51, 52] [55].  Once the cell senses the 
lesion, transducers amplify the damage signal. PI3K like related protein, ataxia 
telengiectasia –mutated kinase (ATM), and the cell cycle checkpoint kinase 2 
(CHK2) respond to DNA DSBs and activate the third class of DDR proteins - the 
effectors [52] [55]. Effectors are responsible for initiating cell cycle arrest and 
facilitating DNA repair. The most notable of these are BRAC1, BRAC2, Nbs1, 
P53, CDC25, and RAD51 [51]. The coordinated activation and signaling of 
sensors, transducers, and effectors enable cells to stall the cell cycle and repair 
DNA damage (Figure 1). 
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Resolution of DNA DSBs: histone modifications and ATM, CHK2, RAD51 
activation  
 In response to detection of DSBs, the cell recruits DDR scaffolding factors 
to modify histones surrounding the break. PARP enzymes, in particular PARP1, 
covalently attaches poly-ADP-ribose (PAR) chains to lysine residues in the amino 
termini of histones [55]. This leads to chromatin re-modeling, promoting 
transcription of genes associated with DNA repair [56]. While PARP attaches 
PAR chains to histones, ATM kinase multimers dissociate into active monomers 
and phosphorylate the histone H2A.X variant on serine 139 (!H2A.X) [49] [56]. 
This triggers dephosphorylation of H2A.X tyrosine 142, allowing the mediator of 
DNA damage checkpoint protein 1 (MDC1) to bind !H2A.X [56]. Once bound to 
!H2A.X, MDC1 recruits the Mre11-Rad50-Nbs1 (MRN) complex to the DNA DSB 
through direct interaction with Nbs1 [57].  The MRN complex then recruits the 
ATM kinase to the DNA DSB site through ATM-Nbs1 interactions [58]. This 
tethers ATM to the DNA DSB site where it phosphorylates nearby H2A.Xs, 
amplifying the DNA damage signal [56]. The MRN complex, acting as an 
endonuclease, resects DNA DSBs to generate 3’ single stranded DNA which is 
then bound by replication protein A (RPA) to prevent SS DNA cleavage [53] [58]. 
Scaffolding proteins, such as BRAC1 and BRAC2, are recruited to the DNA DSB 
and act as a recruitment platform for RAD51. After coating SS DNA to form a 
continuous nucleoprotein filament, RAD51 initiates the homologous chromosome 
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search [58-60]. Upon finding it, RAD51 hydrolyzes ATP and dissociates from SS 
DNA, allowing repair to occur [53] [60] (Figure 1).  
To prevent a damaged cell from cycling before repair is complete, the 
DDR induces a cell cycle arrest mediated by ATM and cell cycle checkpoint 
kinase 2 (CHK2) [50] [52] [55] (Figure 1). ATM phosphorylates CHK2, which in 
turn phosphorylates the CDC25 phosphatase [51] [61]. This inactivates the 
phosphatase, preventing the dephosphorylation of CDC2 that results in G2 
checkpoint release [50, 51]. CHK2 phosphorylation of CDC25 also inhibits Cdk2-
Cdc45 complex activation, preventing chromatin loading and subsequent 
recruitment of DNA polymerase alpha [49]. Thus, CHK2 activation prolongs G2 
arrest, providing time for the cell to repair breaks before entering M phase. In 
addition to inhibiting CDC25 activity, CHK2 promotes genome stability by 
phosphorylating P53 on serine 20 [51]. This prevents the MDM2 ubiquitin ligase 
from targeting it for degradation, allowing it to promote cell cycle arrest by 
inducing a P21 mediated G1 and G2 arrest [51].  Lastly, CHK2 enhances the 
repair of DNA DSBs by phosphorylating the scaffolding protein BRAC2, homing 
RAD51 to the DNA DSB site, facilitating HR [52].  
It is through the coordinated activity of ATM, CHK2, and RAD51 that DNA 
DSBs are repaired, making it easy to envision how disruption of this signaling 
pathway, in particular RAD51, would be catastrophic to cell survival (Figure 1).
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RAD51 promotes cancer cell survival   
Overview 
Cancer cells are characterized by genomic aberrations due to mutations, 
translocations, amplifications, and deletions. When these cells enter and attempt 
to pass through the G2/M cell cycle checkpoint, their damaged and highly 
unstable genomes should trigger cell cycle arrest and initiate apoptosis. Glioma 
cells circumvent this by increasing expression of the DNA repair factor RAD51 
[16] [59]. As RAD51 promotes the repair of DNA DSBs, increased expression 
leads to TMZ resistance and the maintenance of an unstable genome [16].  As 
TMZ+JLK1486 treatment decreases RAD51 expression resulting in cell death, 
how RAD51 acts as survival factor will be examined in detail. 
Discovery and expression patterns 
Genetic studies conducted in the 1960’s suggested that the RecA factor 
was essential for E. coli survival after treatment with DNA damaging agents [53] 
[62]. It was proposed that RecA bound to single stranded DNA and promoted the 
search for the damaged DNA’s homologous chromosome, resulting in 
homologous recombination [53]. In the early 1980’s, a factor with similar 
properties and protein sequence to RecA was cloned in yeast  [63]. Levels 
increased in response to X-rays during late G1 and early S phases of the cell 
cycle, suggesting it alleviated and resolved DNA damage similar to the RecA E. 
coli protein [64, 65]. Later studies confirmed that this eukaryotic DNA repair 
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factor, coined RAD51, performed the same function as the RecA predecessor 
and is essential for HR [53]. 
RAD51’s highly conserved evolutionary sequence suggests it plays a vital 
role in maintaining genome stability. Higher eukaryotes have an 80% protein 
sequence homology with yeast RAD51 and maintain an ~50% similarity with its 
prokaryote RecA homolog [63].  Its expression is highest in the testis, ovary, 
spleen, and thymus, organs that rely on HR for their functionality [63]. Due to the 
essential role it plays during meiosis and recombination, it is not surprising that 
RAD51 knockouts are embryonic lethal [63]. 
RAD51 increased expression promotes cancer cell survival 
 As RAD51 binds to single stranded DNA and is responsible for initiating 
the search for homologous chromosomes, its expression is highest during the 
S/G2 phase of the cell cycle [17] [61, 62]. Cancer cells, however, aberrantly 
express RAD51 and maintain increased expression in G0 and early G1 [62]. 
Increased expression is not due to gene amplification but rather increased 
transcription [16].This enhances the repair of DNA damage accrued during 
chemotherapy and radiation, promoting resistance to both therapies [16]. As a 
result, it is not surprising that Rad51 expression is elevated in a variety of 
cancers, ranging from myeloid leukemia, T cell leukemia, cervical carcinoma, 
melanoma, colon and rectal cancer, and glioblastoma [16] [59] [66]. 
 A twenty-two-year study of GBM patients found 58% of primary tumors 
show increased RAD51 expression versus normal temporal lobe tissue, as was 
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hypothesized [67]. However, counterintuitively, increased RAD51 expression 
correlated with increased survival while decreased RAD51 expression was 
associated with decreased survival [67]. This was unexpected as it was thought 
that decreased RAD51 expression leads to increased survival as tumor cells are 
unable to repair catastrophic DNA damage. A similar expression pattern also 
occurred in recurrent tumors, in that 70% of recurrent tumors had increased 
RAD51 expression compared to their corresponding primary tissue, and patients 
with increased RAD51 expression had prolonged survival (16 months) compared 
to patients’ recurrent tumors with decreased RAD51 expression (4 months) [67]. 
As RAD51 mediates HR, it is expected that increased RAD51 would lead to 
increased proliferation, leading to decreased survival. However, no correlation 
between the proliferative Ki67 marker and RAD51 was found, suggesting tumors 
with increased RAD51 do not have a proliferative advantage over those with 
lower RAD51 expression [67]. There are two possible explanations for why 
increased RAD51 expression did not correlate with decreased survival. First, as 
mRNA was not extracted from either primary or recurrent tissue samples, there is 
no data to indicate if RAD51’s sequence was mutated [67]. Interestingly, 
increased RAD51 expression was found in the cytoplasm of RAD51 high tumors, 
which is rather unusual as RAD51 functions as a nuclear protein [67]. 
Accumulation of nuclear proteins in the cytoplasm, such as P53, is usually 
indicative of mutations resulting in loss of function. However, although a few 
cases have indicated loss of heterozygosity and a miniscule number have 
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mutated RAD51, most GBMs are RAD51 wild type [61].The second explanation 
is that elevated RAD51 is not indicative of survival but rather of cells on the brink 
of mitotic catastrophe. The accumulation of DNA damage resulting from multiple 
rounds of radiation and chemotherapy as well as genomic instability caused by 
aneuploidy could account for increased RAD51 in a viable cell incapable of 
proliferating.  
 A second study in 2012 reported a contradictory finding in which increased 
RAD51 expression correlated with decreased survival, corroborating the 
hypothesis that was proposed but refuted in the above-mentioned study [67].  
Until additional studies are published, the correlation between RAD51 expression 
and clinical survival remains to be determined. As noted above, these 
complications may relate to RAD51 post-translation modifications and subcellular 
localization. However, the fact that RAD51 mediates HR cannot be negated, 
suggesting it is a relevant factor be investigated and targeted. 
RAD51 promotes P53 mutant glioma cell survival during radiation and 
temozolomide treatment  
 Radiation generates DSBs breaks through reactive oxygen species [68]. 
As RAD51 mediates the repair of DSBs, it is not surprising that GBM cell lines 
have increased expression of RAD51 versus normal human astrocytes and that 
increased expression enhances survival following response radiation treatment 
[62].  Conversely, knockdown of RAD51 decreases viability of irradiated glioma 
cells [17].  In vivo studies show that delivery of RAD51 anti-sense 
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oligonucleotides in mice with intracranial implanted glioma cells increases their 
overall survival [17]. Importantly, survival was further increased when RAD51 
anti-sense delivery was combined with radiation [17]. This suggests interference 
of RAD51 sensitizes glioma cells to radiation in vitro and in vivo, making it an 
attractive therapeutic target.  
 Interestingly, irradiation of glioma cells lacking functional P53 produced a 
prolonged G2 arrest that correlated with increased duration of RAD51 foci 
compared to P53 wild type glioma cells or to NHAs [18]. Because P53-deficient 
glioma cells have decreased P21-mediated G1 arrest, they can enter the cell 
cycle with damaged DNA. To avoid apoptosis, they use the G2 delay to resolve 
lingering DNA damage [18]. For this to occur, P53-deficient glioma cells depend 
on ATM activation of CHK2 to initiate G2 arrest. Inhibition of ATM in P53-
deficient cells results in decreased survival following radiation therapy, 
suggesting interference of DNA damage repair is detrimental to gliomas and a 
plausible therapeutic target [18]. 
 TMZ alkylates DNA and generates single strand DNA breaks that are 
converted into DSBs during subsequent rounds of replication [29] [33]. RAD51 
over-expression mitigates TMZ-induced damage in glioma cells by increasing HR 
[62]. For example, glioma cells with stable RAD51 knockdown show decreased 
clonogenic survival following TMZ treatment versus RAD51 empty vector 
transfected control cells [69].  RAD51 control TMZ-treated glioma cells repaired 
and resolved DNA DSBs within 48 hours after treatment. Conversely, treatment 
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of RAD51-suppressed cells with TMZ resulted in sustained DNA DSBs, lasting 
up to144 hours post treatment [70]. Inability to resolve DNA DSBs resulted in 
increased apoptosis, presumably due to decreased HR. To eliminate the 
possibility that RAD51-suppressed cells utilize NHEJ to repair DNA DSBs, the 
effects of a NHEJ inhibitor was explored in RAD51 suppressed TMZ treated 
cells. However, as no significant sensitization resulted from TMZ treatment of 
RAD51 knockdown cells with a NHEJ small molecule inhibitor, it is likely that 
glioma cells with suppressed HR do not use NHEJ to repair TMZ generated DNA 
damage [70]. This is especially important from a therapeutic perspective as 
GBMs become resistant to small molecule inhibitors by activating compensatory 
pathways, negating the inhibitors’ effect. The suggestion that RAD51 suppressed 
cells do not use NEHJ to compensate for HR inhibition further corroborates why 
RAD51 inhibition would be an effective treatment in GBMs.
 Treatment of glioma cells with TMZ results in significant G2 arrest, 
persisting up to 72 hours [62]. The combination of radiation with TMZ leads to 
increased RAD51 foci formation. Conversely, knockdown of RAD51 reduces 
glioma cells’ ability to resolve DSBs accrued from either TMZ or RT, suggesting 
that DNA DSBs persist when RAD51 levels are decreased [62]. Furthermore, a 
significant increase in !H2A.X foci occurred in RAD51 knockdown glioma cells 
following treatment with both radiation and TMZ, supporting the hypothesis that 
increased RAD51 levels promote therapeutic resistance, and interference with 
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RAD51 sensitizes cells to DNA damage caused by radiation or chemotherapy 
[62]. 
RAD51 regulators are mutated or act as oncogenic transcription factors in 
glioma cells 
 Studies in the late 1990’s and early 2000’s suggested that P53 directly 
interacts with RAD51 to negatively regulate its HR function [60] [70]. Co-
immunoprecipitation experiments indicate a direct P53-RAD51 protein-protein 
interaction [71].  Nuclease treatment did not disrupt this, validating that the 
interaction was not mediated by an intermediate nucleic acid [71]. It is thought 
that P53 binding inhibits RAD51’s ATPase activity, preventing it from catalyzing 
strand exchange during HR [71]. This suggests P53 regulates if and when HR 
occurs. P53 inhibition of RAD51-mediated HR prevents repair of DNA DSBs 
during G2 arrest, resulting in cell death due to unresolved DNA damage. 
Supporting this negative regulation, P53 mutant proteins were unable to bind wild 
type RAD51 [71]. Further corroborating this, P53 mutant lines are unable to 
inhibit strand exchange, leading to aberrant and increased use of HR that 
contributes to genomic instability [71].  This is especially interesting in the context 
of cancer development. P53 is the most commonly mutated tumor suppressor 
gene, and loss or mutation of P53 results in genomic translocation, aneuploidy, 
deletions, and inversions [59, 60] [71]. As secondary and recurrent gliomas are 
associated with P53 mutations, it is plausible that glioma cells rely on P53 
mutations to increase RAD51 repair of chemotherapy driven DNA DSBs, further 
#*
strengthening the reason for why RAD51 inhibition may be an effective treatment 
for GBMs [17, 18].  
 Recurrent tumors express higher levels of RAD51 than primary tumors 
and exhibit increased resistance to TMZ [68]. FOXM1, an oncogenic transcription 
factor commonly over-expressed in GBMs, is associated with increased 
resistance to DNA damaging agents such as cisplatin. Comparison of 38 
recurrent versus primary tumor samples indicated increased FOXM1 levels [68]. 
Interestingly, increased FOXM1 expression correlated with increased DNA repair 
pathway mediators such as BRAC2, CHK2, and, of course, RAD51 [68]. This 
suggests that recurrent GBM tumor cells may use FOXM1 to sustain their growth 
and viability by increasing their capacity to resolve DNA damage by increasing 
expression of DDR factors. ChIP as well as luciferase assay reporter assays 
confirm that FOXM1 binds to and regulates the RAD51 promoter [68]. This 
suggests that disruption of FOXM1 may be an alternative means to prevent 
RAD51 expression. Indeed, knockdown of FOXM1 decreases RAD51 
expression, sensitizing recurrent GBM tumor cells to TMZ treatment, while 
rescue of RAD51 in FOXM1 silenced cells rescues survival [68]. This validates 
the hypothesis that glioma cells rely on FOXM1 to increase RAD51 levels to 
promote increased DNA repair, developing chemotherapeutic resistance. As 
RAD51 inhibition leads to decreased viability and increased cell death in 
response to radiation or TMZ, exploring ways to interfere with its role in HR 
remain a viable and active area of interest and research. 
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Targeting the DDR: ATM, RAD51, and CHK2 inhibitors 
Although RAD51 promotes cell survival by increasing the cell’s capacity to 
resolve DNA damage by HR, it also induces genomic instability. Hence, 
increased RAD51 expression is a double-edged sword. On one hand, genomic 
rearrangements may benefit cancer cells by inactivating tumor suppressors or 
placing strong constitutively active promoters in front of oncogenes. Conversely, 
increased HR and genomic relocations may push the cell towards mitotic 
catastrophe. As RAD51 and other DNA repair factors are no longer able to 
mitigate accrued DNA damage, the cell is at risk of undergoing senescence or 
cell death. This weakness may be therapeutically exploited. Treating cells with 
chemotherapies that exacerbate DNA damage, such as TMZ, may overwhelm 
DNA repair mechanisms, pushing the cell towards apoptosis. It is also possible 
that treatment of cells with drugs that inhibit DNA repair sensitize cells to death. 
For example, pre-treatment of cells with an ATM inhibitor before irradiation, 
results in decreased !H2A.X , decreased RAD51 recruitment, and increased cell 
death in glioma cells [55].   
To this end many drugs have been developed against the DDR pathway 
[50] [52]. There are at least six inhibitors of ATM. However, at this time, they are 
unsuitable for clinical use as they inhibit other targets, particularly ATM related 
kinase (ATR), and exhibit high levels of toxicity in patients [52]. At least five 
inhibitors of the CHK2 and RAD51 axis have also been synthesized and are 
currently being studied in vitro. The majority of CHK2 inhibitors function as ATP 
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competitors [52]. Although they sensitize glioma cells to radiation, there are no 
CHK2 inhibitors in the clinic for GBMs at this time due to lack of permeability, 
specificity, and synergy with DNA damaging agents [52]. Screens of over 
200,000 compounds from the NIH repository as well as over 100,000 molecules 
from the DIVERSet Chembridge Corporation library identified several promising 
RAD51 candidates [52].  Although these candidates are in early stages of 
development, there is exciting data suggesting some specifically inhibit RAD51 
HR by covalently binding to its cysteine residues, preventing DNA binding and 
nucleoprotein filament formation [52].  
At this time, the best-case scenario for inhibiting DDR activity is the use of 
combination therapies that result in synthetic lethality. For example, Gleevec, an 
FDA approved drug that inhibits the Abl kinase, decreases RAD51 protein, radio-
sensitizing glioma lines [72]. It is easy to envision how combining Gleevec, which 
indirectly inhibits HR, with either a PARP inhibitor, such as Olaparib, or an ATM 
inhibitor, would increase sensitivity of gliomas to RT or chemotherapies. This 
would prevent repair of and lead to accumulation of both single and double 
stranded DNA breaks. These exacerbations would push the already tumultuously 
unstable genomic background of the cell towards genetic collapse, resulting in 
death. This proof of principle concept was validated when PARP inhibition in 
either a RAD51 knockdown or HR deficient cellular background was lethal, 
demonstrating the potential of harnessing synthetic lethality [73].  
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Summary 
These studies serve as models for why combination therapies are the best 
therapeutic approach to cancer. Although TMZ induces DNA damage that may 
push the cell towards apoptosis, simultaneously preventing repair of DNA 
damage and exacerbating a second reliant pathway increases the likelihood of 
lethality. To understand why the ER stress inducing JLK1486 agent results in a 
robust cell death response when combined with TMZ requires understanding of 
key players of the ER stress response and how the DDR and ER pathways 
crosstalk. 
Introduction to the Endoplasmic Reticulum and Unfolded Protein Response 
Rationale 
Unresolved ER stress is detrimental as it triggers ER mediated death 
through three key players, PERK, ATF4, and CHOP [10] [39] [74]. The ER stress 
signaling axis and its players will be discussed in detail, as they are responsible 
for decreasing glioma cell viability in response to TMZ and JLK1486 treatment.  
Overview of ER function, requirements, stress triggers, and response 
The endoplasmic reticulum (ER), an evolutionary conserved organelle 
present in all eukaryotic cells, is required for the synthesis and folding of secreted 
and transmembrane proteins [10] [39] [75]. The ER must (1) maintain high 
luminal levels of ATP to sustain the energy demands of protein folding, (2) an 
oxidizing environment to facilitate the formation of disulphide bonds, and (3) 
increased calcium and molecular chaperone levels to guide and stabilize folding 
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proteins so that correct tertiary structures are achieved [39] [75].  This process is 
dependent on favorable cell conditions promoting ER homeostasis and is easily 
disrupted. 
The ER is extremely sensitive to cellular perturbations such as hypoxia 
and decreased levels of nutrients, calcium, ATP, iron, amino acids, and 
molecular chaperones [39] [75]. These changes not only alert the ER to 
unfavorable cellular environments but also impair ER function, resulting in 
activation of the ER stress response [10] [39] [75]. Radiation, which generates 
reactive oxygen species, as well as infection, hyperplasia, and the accumulation 
of unfolded and misfolded proteins also activate the ER stress response [75].  
The initial response to ER stress is twofold. The first is inhibition of protein 
translation [10] [39]. This not only alleviates the number of nascent proteins 
shuttled into the ER for folding but also reduces the cellular demand for ATP. 
This is of particular importance if ER stress is triggered by hypoxia as decreased 
oxygen forces the cell to shift from aerobic metabolism to anaerobic glycolysis. In 
addition, translational inhibition depletes cyclin D1 levels, resulting in a G1 arrest, 
preventing stressed cells from propagating [76] [77]. The second ER stress 
response is increased expression of genes that enhance amino acid metabolism, 
molecular chaperones, protein transportation, and formation of disulfide bonds 
[10] [39].  This allows the ER to fold or refold proteins already within its lumen. 
However, because folding proteins is a cost effective process, there is a finite 
time by which this must occur, or else the unfolded proteins are targeted for 
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proteasomal degradation, a process known as ER associated degradation 
(ERAD) [10] [39]. This prevents the ER from using more energy and reduces the 
number of unfolded proteins present in the ER. This initial pro-survival response 
is tightly and carefully regulated as it is only meant to resolve stress and promote 
survival in non-aberrant cells.  
The ER pro-survival response is mediated by PERK, ATF6, and Ire1 
The pro-survival response mediated by the ER is due to the coordinated 
activation and regulation of three transmembrane ER receptors, PERK, ATF6, 
and Ire1 [10] [39] [75]. Glucose regulated protein 78 (Grp78/BiP), a molecular 
chaperone and member of the heat shock protein 70 family, binds to the luminal 
domain of all three ER receptors, rendering them inactive during ER homeostasis 
[10] [39] [78, 79]. When ER stress occurs, BiP dissociates from the receptors, 
triggering their activation [10] [39] [80].  
The first arm of the ER stress response is activated by PKR like kinase 
(PERK) homodimerization and autophosphorylation. PERK is a serine/threonine 
kinase that regulates eukaryotic initiation factor two alpha (eIF2"), a key member 
of the 43S initiation complex required for cap dependent mRNA translation [80, 
81].  Activated PERK phosphorylates eIF2" on serine51 (P- eIF2"), preventing it 
from forming the 43S complex, resulting in inhibition of cap dependent translation 
[39] [81] [82].  Attenuation of protein translation serves two purposes. First, as 
earlier discussed, it reduces the demand of the ER to fold newly synthesized 
proteins, and, second, increases translation of cap independent transcripts, such 
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as activating transcription factor four (ATF4), which alleviate ER stress by 
increasing amino acid metabolism and molecular chaperone levels [10] [39] 
(Figure 2). 
The second arm of the ER stress response is regulated by the 
transmembrane receptor activating transcription factor 6 (ATF6) [10] [39]. 
Dissociation of BiP from its luminal domain frees its Golgi localization sequence.  
Once localized to the Golgi, two site specific protease (Sp-1, Sp-2) cleave it, 
revealing a basic leucine zipper domain, inducing translocation to the nucleus to 
drive the expression of pro-survival factors such as BiP, X box binding protein 1 
(XBP-1), and disulphide isomerase, which catalyzes the formation of disulphide 
bonds [10] [39] (Figure 2). 
The third arm of the ER stress response is mediated by the 
transmembrane receptor Ire1, which functions as both a serine /threonine kinase 
and an endoribonuclease [10] [39]. After BiP dissociation, Ire1 dimerizes, 
autophosphorylates, and alternately splices XBP1 mRNA, resulting in XBP1 
transcription factor activity [10] [39]. XBP drives the expression of molecular 
chaperones, increases phospholipid synthesis, as well as p58 that serves as a 
negative regulator of PERK, terminating the PERK – P- eIF2" mediated signaling 
cascade initiated by ER stress [10] [39] (Figure 2). 
 The activation of PERK, ATF6, and Ire1 in response to ER stress 
promotes cell survival by preventing cell cycle entry, stalling protein translation, 

$(
The ER pro-death response is mediated by CHOP 
After ER stress is resolved, BiP re-associates with the luminal domains of 
PERK, ATF6, and Ire1, switching off the ER stress induced signaling cascade. 
However, if ER stress is irreversible or if the cell is in a chronic state of stress, 
PERK, ATF6, and Ire1 induce expression of the pro-apoptotic transcription factor 
C/EBP homologous protein (CHOP) to initiate a pro-death response [39] [75]. 
This response induces either extrinsic or intrinsic mediated apoptosis through 
release of mitochondrial cytochrome C activating the effector caspase 3 or by 
death receptor activation by TRAIL binding [83-87]. Induction of cell death in 
response to unresolved ER stress serves to protect the organism; however, 
cancer cells often bypass this and instead manipulate the ER response to 
promote survival and growth in unfavorable environments [10] [39].  
The ER stress response promotes cancer cell survival 
Overview 
Solid tumors are characterized by rapidly proliferating cells that outstrip 
available blood vessels and deplete available nutrients to create regions of 
hypoxia [7] [41].  To alleviate this, GBMs promote blood vessel development, but 
these networks are leaky, inefficient, and often form dead-end junctions [4] [8] 
[14] [21]. This aberrant vasculature contributes to decreased nutrient delivery as 
well as a buildup of toxic metabolic wastes, leading to a state of chronic ER 
stress [8]. This state triggers the pro-death ER stress response through activation 
of the pro-apoptotic transcription factor CHOP.  However, cancer cells 
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circumvent this by up regulating ER factors that promote survival such as BiP, 
XBP, PERK, and ATF4, preventing CHOP induction [14] [39] [88]. 
BiP, Ire1, and PERK promote cancer cell survival    
BiP over-expression promotes cancer cell survival by holding the ER 
stress response in check, preventing sustained ER stress from initiating the pro-
death response [39]  [89, 90]. Evidence suggests that BiP binds to and blocks the 
cleavage of caspase 7 and 12 as well as to BIK/BAX, preventing the release of 
cytochrome C from mitochondria [91]. Additionally, because BiP serves as a 
molecular chaperone, elevated expression increases the folding capacity of the 
ER [92]. This helps to compensate for the increased number of mutated proteins 
in cancer cells that require multiple folding attempts. BiP up-regulation has been 
found in a myriad of cancers, including breast, stomach, gastric and brain [15, 
93, 94]. BiP expression in GBM cells correlates with increased cell survival and 
proliferation while knockdown results in decreased survival and cell growth [13] 
[15]. A mouse mammary model showed BiP heterozygous mice have decreased 
tumor progression and increased cell death, resulting from activation of caspase 
3 and 7, suggesting that BiP mitigates in vitro ER stress, supports survival and 
proliferation, and promotes tumorigenesis [39] [95]. 
 The IRE1/XBP pathway has also been implicated in promoting cancer cell 
survival. XBP is often over-expressed in breast cancer cells and over-expression 
of spliced XBP contributes to the development of multiple myeloma in transgenic 
mice [96, 97].  Human fibrosarcoma cells deficient in XBP are unable to initiate 
$*
tumors in SCID mice, suggesting XBP adapts cells in response to ER stress [98].  
Additionally, prolonged IRE1 signaling has been shown to promote cell 
proliferation without activating cell death [99]. 
We will focus on how the PERK-eIF2"-ATF4-CHOP pathway affects 
cancer development and progression as JLK1486 treatment exacerbates this 
axis. 
PERK 
PERK identification and function 
 Delineation of the ER stress response pathway resulting in eIF2" 
phosphorylation and translational inhibition was first characterized in yeast [100]. 
GCN2, which is conserved and expressed in all eukaryotic cells, was the first 
kinase identified to phosphorylate eIF2" in response to amino acid deprivation 
[101-103]. This led to the discovery of two uniquely expressed mammalian 
kinases, PKR (double-stranded RNA dependent kinase) and HRI (heme 
regulated inhibitor kinase), which phosphorylate eIF2" in response to viral 
infection and decreased heme concentrations [104, 105]. Both kinases, when 
activated, recapitulate stalled mRNA translation. However, as both PKR-/- and 
GCN2-/- deficient cells were able to attenuate mRNA translation in response to 
ER stress inducing agents (ERSAs), it suggested that a third kinase was 
responsible for eIF2" phosphorylation in response to ERSAs [102]. In the late 
1990’s and early 2000’s, three separate groups identified a novel mammalian 
serine/ threonine kinase that phosphorylates eIF2" in response to ERSAs, such 
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as thapsigargin (THAP) which releases calcium from the ER, and tunicamycin 
(TUN) which blocks N-linked glycosylation [82] [102] [106]. As the kinase 
localized to the ER and had a similar, but not identical, luminal domain amino 
acid sequence as PKR, it was named PERK, for PKR-like kinase [102].  Its 
kinase activity was validated as both serine and threonine residues were found to 
be phosphorylated and, more importantly, could phosphorylate eIF2" [82] [102] 
[108]. Mutation of PERK’s kinase domain results in a PERK that is unable to 
phosphorylate eIF2" and inhibit mRNA translation in response to ERSAs, 
validating its kinase role in ER stress [82] [102]. The identification of four eIF2" 
kinases, each one responding to a unique ER stress trigger, demonstrates how 
important eIF2" phosphorylation is to regulating the ER stress response and how 
tightly controlled the response is.  
PERK expression patterns 
PERK expression was detected in 50 different human tissues, including 
brain, with increased levels corresponding to tissues involved in secretion, such 
as the stomach, salivary gland, pituitary, and pancreas [82]. This corroborates 
PERK’s role in ER function and protein folding.  Although PERK is expressed in a 
variety of organs, PERK knockout is not embryonic lethal. Instead, mice develop 
early onset diabetes by 4 weeks, accompanied by increased activation of IRE1, 
suggesting prolonged ER stress [107]. These mice ultimately die by 8 weeks due 
to increased apoptosis in pancreatic islet cells [109]. 
PERK activation and pathway delineation 
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In the absence of ER stress, BiP binds to PERK’s luminal domain, 
preventing dimerization and activation of the receptor [79]. Treatment of cells 
with ERSAs decreases BiP association, as suggested by reduced co-
immunoprecipitation, promoting receptor oligomerization and 
autophosphorylation [80]. The precise mechanism leading to BiP dissociation has 
not been elucidated, but it is plausible that BiP, acting as a molecular chaperone, 
dissociates from the luminal domains of the receptors to bind unfolded or 
misfolded proteins in the ER. Alternatively, it is possible that PERK undergoes 
conformational changes in response to ER stress, resulting in BiP dissociation. 
Regardless of the mechanism, dissociation of BiP is required for the dimerization 
of all three ER receptors and their subsequent activation [80]. 
 Activated PERK phosphorylates eIF2" on serine 51 [81] [83]. This 
particular site is important as eIF2" must bind GTP to form the 43S initiation 
complex, which is required for cap dependent mRNA translation [108]. 
Phosphorylation of eIF2" on serine 51 prevents the eIF2# guanine nucleotide 
exchange factor (GEF) from exchanging GDP for GTP [108]. Although eIF2" 
serine 51 phosphorylation blocks the eIF2# GDP-GTP exchange, the serine 51 
phosphorylation increases eIF2" ‘s binding affinity for eIF2#, sequestering the 
GEF, reducing formation of other 43S complexes, resulting in decreased mRNA 
translation. 
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PERK promotes in vitro cancer cell survival 
 Phosphorylation of eIF2" by PERK is essential for promoting survival of 
cells experiencing ER stress [81] [83]. If PERK is unable to stall translation, 
protein folding demands overwhelm the ER as its calcium, ATP, molecular 
chaperones, and oxygen levels are unbalanced. Unfolded and misfolded proteins 
accumulate in the ER lumen, causing ER swelling and activation of the unfolded 
protein response (UPR). Cell death soon follows due to ER incapacitation. 
PERK deficient mouse embryonic fibroblasts (MEFs) are incapable of 
attenuating protein translation in response to ER stress inducing agents, such as 
THAP or TUN [81] [83]. Instead of dissociating polyribosomes into monosomes, 
PERK deficient ERSA treated cells have increased polyribosomal formation and 
continue to synthesize proteins [81] [83]. To mitigate their stress, PERK deficient 
MEFs rely on prolonged activation of other arms of the ER stress pathway, in 
particular, Ire1. However, protracted Ire1 signaling is unable to robustly inhibit 
translation in response to ERSAs, and cells show decreased survival due to 
caspase 12 cleavage [81] [83]. PERK rescue reverses the phenotype, resulting in 
phosphorylation of eIF2", stalled mRNA translation, and increased survival [81] 
[83]. This response highlights the important role PERK plays in inhibiting protein 
translation and promoting cell survival [108].  It also accounts for why cancer 
cells increase PERK expression to promote survival. 
 Although PERK mediated eIF2" phosphorylation inhibits translation of 
most mRNAs, a microarray study identified a subset of proteins with increased 
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translation in response to hypoxia activated PERK. Isolation of mRNAs from 
polysomes in PERK +/+ versus PERK -/- hypoxia treated MEFs revealed a four- 
fold increase in mRNAs associated with angiogenesis, cell adhesion, protein 
transportation and folding [109]. Interestingly, a ten-fold increase in VEGF and 
type I collagen inducible protein, key to blood vessel formation, was found in 
PERK +/+ hypoxic treated MEFs compared to PERK -/- MEFs [111]. 
Furthermore, PERK+/+ hypoxic treated MEFSs had increased expression of 
matrix metalloproteinase 13, a protease that cleaves the extracellular matrix in 
tissues, suggesting PERK promotes metastasis [111]. Mammary epithelial cells 
increase PERK activation in response to loss of attachment, supporting PERK 
mediated survival following loss of attachment [110]. Additionally, treatment of 
human fibrosarcoma cells undergoing EMT with the PERK inhibitor, GSK414, 
resulted in 70% cell death while non-treated cells had only 20% cell death during 
EMT [111].  Critical to PERK’s role in supporting survival during EMT, attached 
fibrosarcoma cells did not undergo significant cell death in response to GSK414 
[113]. Overall, this suggests PERK increases translation of mRNAs that promote 
blood vessel development in response to hypoxia while promoting survival during 
EMT, both processes critical to the survival of cancer cells in unfavorable 
environments [111-113]. 
 PERK activation may protect cancer cells and promote their growth by 
creating a cytoprotective response to sublethal doses of ER stress. When MEF 
PERK+/+ cells were exposed to two hours of hypoxia, allowed to recover for four 
%%
hours, and then re-incubated for an additional 24 hours at low oxygen, they 
exhibited increased survival in comparison to cells not pre-exposed to hypoxia 
before the 24 hour incubation [11]. This also held true for ERSA treatment. MEF 
PERK+/+ treated with THAP prior to incubation for 24 hours at low oxygen 
survived at higher rates than cells not pre-treated with THAP before the 24 hours 
exposure to low oxygen levels [11]. This suggests that activation of PERK in 
response to low levels of ER stress may prime the pathway for increased survival 
in response to future stress [11]. This is critical as cancer cells, GBMs in 
particular, are resistant to chemotherapies. It is possible that drug treatments 
utilizing multiple low doses may trigger PERK mediated cytoprotection instead of 
inducing cell death.  Furthermore, sub-lethal doses of radiation therapy (RT) may 
pre-condition cells to clear generation of reactive oxygen species (ROS), 
reducing RT efficacy.  This is plausible as PERK activation results in 
phosphorylation of its downstream target Nrf2, which increases the expression of 
enzymes that clear harmful intracellular ROS [112]. This would protect cancer 
cells from RT-ROS-generated single and double strand breaks, maintaining DNA 
integrity.  
Knockdown of PERK in human breast and esophageal carcinoma cells 
resulted in activation of DNA damage response and checkpoint proteins, 
inducing a G2/M arrest and decreased proliferation [42] [114]. Inhibition of cell 
cycle progression and activation of the DNA damage response was due to 
accumulation of ROS and a two-fold increase in DSBs [114]. This suggests that 
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PERK contributes to RT resistance by decreasing ROS that would normally 
result in single and double strand breaks [42] [114].  Cancer cells utilize PERK to 
circumvent chemotherapy and RT induced growth arrest and cell death and to 
protect their survival against current ER stress and, in some cases, future stress. 
This is of particular interest to our studies of TMZ+JLK1486 treatment as it 
suggests crosstalk between the ER stress response and DNA damage response 
pathways (DDR). JLK1486 may not only exacerbate ER stress but also increase 
DDR dependence, increasing cells sensitivity to TMZ.  
PERK promotes in vivo cancer cell survival  
 PERK promotes the in vitro survival and proliferation of cancer cells and 
plays an integral role in promoting in vivo tumorigenesis. PERK deficient K-RAS 
transformed MEFs formed tumors at slower rates with decreased tumor volumes 
than PERK +/+ K-RAS transformed cells [110].   Sectioning of PERK deficient 
tumors indicated increased apoptosis in hypoxic regions [110,111]. Conversely, 
PERK wild type K-RAS cells in hypoxic regions exhibited decreased apoptosis, 
suggesting PERK was able to mitigate the effects of low oxygen [110,111]. PERK 
+/+ transformed MEFs had increased levels of P-eIF2" in cells in hypoxic regions 
while PERK deficient tumors did not [81[ [83] [110]. Furthermore, expression of a 
non-phosphorylatable eIF2" in K RAS PERK +/+ transformed MEFs resulted in 
decreased survival and increased apoptosis due to caspase and PARP 
cleavage. Decreased tumor volume correlated with cells in hypoxic regions 
unable to phosphorylate eIF2" [110]. This suggests that tumors with PERK 
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expression have not only a survival but also a proliferative advantage over PERK 
deficient cells in response to hypoxia [11] [81] [83] [110,111]. The survival 
advantage mediated by PERK could be an attractive therapeutic target, however, 
long term knockdown of PERK led to increased genomic instability in normal 
cells, making PERK inhibition a double edged sword in that the initial knock down 
may increase RT and chemotherapy efficacy but long term knockdown may 
result in transformation of normal, bystander cells [114]. 
Additionally, PERK induction may increase angiogenesis, promoting tumor 
cell survival in hypoxic environments. Sectioning of PERK  -/- K-RAS transformed 
tumor sections when compared to PERK +/+ tumors exhibited decreased blood 
vessel density, with the majority of blood vessels presenting as non-functional 
[111]. The aberrant vasculature, resulting from cuboidal instead of elongated 
endothelial cells, formed vessels densely filled with endothelial cells instead of 
hollow structures that allow blood flow [111]. The accumulated endothelial cells 
prevent blood flow and increase pressure within the vessel.  This, along with the 
misshapen blood vessels and the lack of cell-to-cell adhesion along the vessel, 
likely contributes to the 22% of PERK -/- tumors that hemorrhage [111].   
Although PERK may increase vasculature formation to alleviate hypoxia, it 
is detrimental for cells to remain in this chronic state. To alleviate this, cancer 
cells metastasize to new locations that are more favorable. PERK promotes the 
in vitro migration of breast and melanoma lines by increasing survival during 
EMT and by increasing enzymes that degrade ECM [42] [112]. This was 
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recapitulated in vivo as PERK promoted increased metastasis of breast cancer 
cells in a mouse mammary carcinoma model. Conversely, PERK deficiency 
resulted in decreased metastasis [114]. This suggests that PERK not only 
contributes to blood vessel development to promote tumorigenesis but also 
provides a mechanism for cancer cells to exit unfavorable conditions.    
In addition to promoting blood vessel development and metastasis, PERK 
protects cancer cells from DNA damage.  PERK-/- mammary carcinoma cells 
form tumors with decreased volume versus wild type mammary carcinoma cells 
[114].   This was due to increased levels of ROS that correlated with decreased 
expression of enzymes, such as Nrf2, that clear ROS from the cell [114]. 
Sectioning of PERK -/- tumors found that increased ROS correlated with 
increased DNA damage, specifically elevated levels of DNA DSBs  [114]. This 
suggests that decreased tumor formation is the result of catastrophic DNA 
insults. PERK activation promotes survival in regions of hypoxia, maintains DNA 
stability by reducing DNA damage, and increases tumor cell proliferation and 
volume [81] [83] [110,111] [114]. As JLK1486 induces prolonged ER stress, it is 
easy to envision how the addition of further insults, such as the DNA alkylating 
agent TMZ, would be deleterious to cell survival. 
PERK contributes to GBM development 
Although the majority of PERK’s in vitro and in vivo contributions to cancer 
cell survival and tumorigenesis has been studied in transformed MEFS and 
breast cancer lines, recent data suggests a role for PERK mediated GBM cell 
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survival. As the ER stress response is evolutionary conserved, it is reasonable to 
think PERK mediated mechanisms of protection plays a role, at least to some 
degree, in GBM tumorigenesis.  Indeed, PERK expression increases with glioma 
tumor grade, with grade IV GBMs presenting with higher PERK expression than 
grade III which exhibit higher levels than grade II which are elevated in 
comparison to normal brain tissue [12]. This suggests that PERK is important for 
tumor progression and may be vital for GBM cell survival. Treatment of PERK-
silenced GBM established lines with ERSAs, such as TUN or low glucose media, 
decreased viability and increased apoptosis [12]. This suggests PERK mediates 
a similar mechanism of cell protection as observed in breast and transformed 
MEFs.  Knockdown of PERK in the U87MG GBM cell line resulted in decreased 
tumor formation, implying PERK promotes GBM tumorigenesis, as observed in 
breast cancer and transformed MEFs [12]. 
PERK summary 
PERK is an evolutionarily conserved serine / threonine kinase ER receptor 
that promotes survival in unfavorable conditions, such as hypoxia, or in response 
to ERSAs [10] [39].  It enhances cancer cell survival and supports tumorigenesis 
by stalling mRNA translation, while activating pathways that eliminate ROS, 
decreasing DNA damage, increasing cell cycle progression, promoting blood 
vessel formation, improving survival after loss of cell-to-cell attachment, and 
mediating cytoprotection in response to sub lethal doses of RT and ERSAs [11] 
[42] [81] [83] [102] [108] [110,111] [114].  PERK inhibition sensitizes cancer cells 
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to ERSAs and RT, suggesting drugs that disrupt PERK activation may improve 
the efficacy of RT and chemotherapeutic agents [81] [83] [110,111] [114]. 
However, drugs that effectively target PERK remain elusive due to issues of 
specificity and achievable clinical concentrations [10] [39]. Perhaps the most 
feasible approach to disrupting PERK mediated survival is not the targeting of 
PERK itself but rather the ER stress response as a whole. Two ways to address 
this have been suggested. The first utilizes drugs to inhibit the ER pro-survival 
responses while the second uses drugs that further increase ER stress to 
overwhelm and incapacitate the ER [10] [39]. 
 We utilized the second approach, combining the novel ER stress-inducing 
agent, JLK1486, with the standard chemotherapeutic agent, temozolomide 
(TMZ), to induce sustained ER stress while generating DNA DSBs [19]. To 
understand why TMZ+JLK1486 results in unresolved ER stress and apoptosis, 
we must understand two PERK-regulated proteins, activating transcription factor 
4 (ATF4) and CAAT/enhanced binding homologous protein (CHOP).  Persistent, 
irreversible ER stress activates ATF4 and CHOP, switching the PERK mediated 
pro-survival response to one of pro-death, as observed in TMZ+JLK1486 treated 
cells [19] [75]. 
ATF4 
ATF4 identification and function 
Eight activating transcription factors (ATFs) were identified in the late 
1980’s that recognized and bound the cAMP responsive element (CRE) 
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consensus sequence 5’ GTGACGT A/C A/G 3’ [113, 114]. Each ATF is 
expressed from a different gene locus, resulting in related but distinct family 
members [116]. Of the eight ATFs, six have basic leucine zipper motifs [116]. 
The basic domain recognizes and binds DNA consensus sequences while the 
unique leucine domain promotes either homo or heterodimerization [116]. This is 
essential to regulating gene expression as it creates a diverse pool of factors that 
can activate or repress a wide variety of genes with similar consensus 
sequences, resulting in specific cell, tissue, organ, and developmental 
expression. 
In particular, activating transcription four (ATF4), can form cross family 
bZIP dimers, most notably with CAAT box/ enhancer binding proteins (C/EBP), 
which tend to regulate differentiation as well as inflammatory responses [116, 
[115, 116]. The crystal structure of ATF4 associated with C/EBP indicates that 
ATF4’s alpha helix is ordered [118]. This suggests that when ATF4 is bound to a 
C/EBP family member it can still recognize and bind its consensus sequence 
[118] . Therefore, depending on its binding partner, ATF4 can positively or 
negatively regulate gene expression [117]. For example, ATF4 can bind to the 
symmetric CRE sequence in the somatostatin gene [117]. However, when ATF4 
dimerizes with the C/EBP # family member, the complex synergistically increases 
somatostatin expression [117].  Conversely, dimerization of ATF4 with C/EBP # 
prevents C/EBP # from binding to C/EBP sequences, repressing transcription of 
genes that would be increased in response to C/EBP # homodimers [117]. 
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Therefore, expression patterning of genes depends on the increasing and 
decreasing ratios of ATFs to C/EBPs [115] [117].  This is of particular importance 
during ER stress as PERK activation results in increased ATF4 protein levels, 
making it easy to surmise how one TF could effect a multitude of genes. 
ATF4 expression patterns 
Identification of a CRE sequence in human T cell receptors led to the 
isolation of human ATF4 [117, 118]. The transcript was ubiquitously expressed in 
brain, kidney, liver, spleen as well as T and B cells [115] [119,120]. Although the 
transcript is quite stable, the protein has a very short half -life, less than 30 
minutes [117]. This allows for tightly regulated gene expression in response to 
fluctuating environmental conditions.  
For ATF4 knockouts, 70% of mice die between ED 17.5 and day 14 post 
natal, leaving only 30% of mice to survive to adulthood [115]. The surviving mice 
develop serve micropthalmia due to lack of eye lens development [115]. This is 
caused by p53-mediated apoptosis in secondary lens fiber cells during 
differentiation [119]. Loss of ATF4 is thought to promote apoptosis as it is not 
present to heterodimerize and sequester ZIP, a kinase that induces apoptosis 
when homodimerized [121].  This is another example of how ATF4 can act as a 
repressor and regulate different outcomes, such as cell survival or cell death, 
depending on its binding partner. It is rather surprising that ATF4 knockout only 
results in lack of lens development as its transcript is found in a variety of organs.  
However, because ATF4 belongs to such a large, diverse family, another ATF 
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member may compensate for its loss, but is unable to do so in the eye.  This 
again highlights how specific ATF expression affects cell survival. 
ATF4 pathway delineation 
Where and how ATF4 fit into the mammalian ER stress response was 
unknown until the mechanism regulating GCN4, the yeast homolog of ATF4, was 
characterized. In response to amino acid deprivation, yeast phosphorylate eIF2", 
triggering inhibition of mRNA translation [108]. However, GCN4 mRNA 
translation is up-regulated in response to eIF2" phosphorylation [81] [83] [108]. 
Sequence analysis of GCN4 revealed an upstream open reading frame (uORF) 
that inhibited translation when eIF2" was unphosphorylated but, conversely, 
facilitated it when it was [120, 121].  As mammalian cells also phosphorylate 
eIF2" in response to ER stress, it was suggested that mammalian ATF4 
regulation might mimic GCN4s. A database of 7,000 mammalian transcription 
factors was compiled to specifically look for transcription factors that contain 
uORFs and whose translation is inhibited when eIF2" is not phosphorylated and 
is increased when it is [81] [83].  ATF4 was identified and found to contain two 
uORFs, both which are conserved from invertebrates to mammals [81] [83] [122]. 
Protein, not mRNA levels, increased within 24 hours in response to hypoxia and 
increased levels of Ca2+, suggesting ATF4 is regulated post transcriptionally in 
response to ER stress [81] [83] [115]. To verify ATF4 translation was indeed 
regulated by its’ uORF, the AUG start codon found in the second uORF was 
mutated to AUA and used to drive expression of luciferase. Mutation resulted in 
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luciferase expression with or without the ERSA THAP [83]. Conversely, the 
control non-mutated AUG luciferase reporter only exhibited luciferase expression 
in response to THAP treatment, suggesting ATF4 is regulated by its uORFs in 
response to ER stress [83]. 
If ATF4 is regulated by its uORF in response to phosphorylated eIF2", ER 
stress induction should increase ATF4 protein levels. Indeed, when cells are 
treated with ERSAs such as THAP, DTT, or TUN, ATF4 protein increases [81] 
[83]. When ATF4 levels increase is cell and context dependent. For example, 
NIH 3T3 cells are able to increase ATF4 protein levels within four to eight hours 
after THAP treatment while wild type MEFs up-regulate ATF4 protein expression 
within two hours of THAP treatment [76, 123]. Regardless of the time of 
induction, ERSA-induced ATF4 protein expression is dependent on PERK. PERK 
deficient cells have constitutive high levels of ATF4 mRNA but are unable to 
translate it in response to ERSA treatments as they cannot phosphorylate eIF2" 
[81] [83]. In this case, increased ATF4 protein levels in response to ERSA 
treatment, is dependent on PERK mediated phosphorylation of eIF2" [81] [83]. 
This also suggests that treatment of glioma cells with JLK1486, which acts as an 
ERSA, will lead to PERK mediated ATF4 translation. 
Further confirming that ATF4 protein increases in response to ER 
stresses, ATF4 mRNA was associated with polyribosomes during ERSA 
treatment, hypoxia, or amino acid deprivation [81] [83]. Conversely, in unstressed 
cells, ATF4 mRNA is mainly associated with monosomes, indicating lack of 
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translation [81] [83]. Additionally, cell stress induced a four-fold incorporation of 
labeled S35 methionine into ATF4 protein, verifying that ER stress induction 
regulates ATF4 by increasing its translation in a cap independent manner [81] 
[83]. 
The three arms of the ER stress response pathway carefully regulate 
ATF4 expression through phosphorylation of eIF2" [10] [39] [81] [83].  This 
maintains organism integrity by preventing stressed cells from entering the cell 
cycle, giving cells time to resolve stress and the chance to re-enter the cell cycle.  
If cells are unable to resolve the initial stress response or enter a state of 
prolonged or chronic stress, the pro-survival response switches to one of pro-
death [75]. ATF4 regulates this switch by upregulating the expression of 
transcription factors that induce mitochondrial-mediated apoptosis [81] [83] [124, 
125]. Cancer cells circumvent ER induced death by either suppressing or 
mutating pro-apoptotic factors or over expressing pro-survival factors in the 
mitochondrial pathway to promote viability [87] [123].
 ATF4 promotes in vitro survival 
Increased ATF4 expression promotes cell survival in disadvantageous 
environments. Its expression is elevated in several human cancers, including 
cervical, breast, skin, and GBMs [87] [110] [113] [120]. As previously addressed, 
ATF4 can act as either a repressor or an activator, depending on its binding 
partner, allowing it to regulate a multitude of pro-survival responses that cancer 
cells depend upon for survival [116, 117] [119]. 
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 In response to ER stress, ATF4 increases expression of the pro-survival 
molecular chaperone BiP, facilitating protein folding to promote cell survival.  The 
finding that ATF4 increases BiP in response to ERSAs was extremely important 
because it was previously thought that only ATF6 could induce BiP expression 
[125]. Analysis of the BiP promoter showed the presence of three ER stress 
response elements (ERSE) that ATF6 recognizes, as well as an ATF-CRE like 
sequence [125] [126]. ATF4, when dimerized with CREB1, is able to recognize 
and bind the ATF-CRE like sequence, increasing BiP expression in response to 
ERSAs [125]. The presence of both sequences is vital for a prompt response to 
ER stress triggers. Cells lacking ERSEs have decreased BiP induction in 
response to THAP treatment and ATF4 mutant cells with ERSE and ATF-CRE 
sequences are unable to increase BiP to the same level as ATF4 wild type THAP 
treated cells [125]. This suggests that ATF4 and ATF6 synergistically increase 
BiP. That two arms of the ER stress pathway, ATF6 and ATF4, are both capable 
of increasing BiP expression speaks to the important role BiP plays in alleviating 
ER stress and how quickly survival factors can be activated in response to 
stress.  
To alleviate ER stress and promote recovery, ATF4 contributes to the two 
to ten-fold increase observed in genes that regulate amino acid biosynthesis 
[127]. For example, ATF4 binds to the nutrient sensing response element in the 
promoter of asparagine synthetase, increasing expression of the enzyme that 
converts aspartic acid to asparagine [128]. This increase in amino acid 
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production facilitates the translation of mRNAs backlogged in the ER as well as 
increases the translation of proteins triggered by cap independent mechanisms in 
response to phosphorylated eIF2".  
In addition to increasing levels of molecular chaperones and amino acid 
production, ATF4 can also protect cells from hypoxia by inducing autophagy 
[113]. A microarray study in breast cancer cells indicates that ATF4 increases 
expression of MAPILC3B (LC3B), a key member of the autophagosomal 
membrane, in response to hypoxia [129]. Sequence analysis of LC3B promoter 
region indicated a 5’ consensus sequence in the UTR that ATF4 can recognize 
and bind to [131]. Increased expression of LC3B, which occurs after 48 hours 
exposure to hypoxia, suggests it may not be induced until levels of ATF4 
accumulate in response to eIF2" phosphorylation [131]. Knockdown of ATF4 
results in a 65% decrease in LC3B mRNA, suggesting that it in part regulates its’ 
transcription [131]. Increased LC3B and subsequent induction of autophagy 
correlates with increased cell survival and decreased cell death in breast cancer 
cells exposed to hypoxia, implying that ATF4 increases cancer cell survival in 
detrimental conditions. 
ATF4 promotes in vivo survival of cancer cells 
Solid tumors are dependent on PERK mediated phosphorylation of eIF2" 
to activate ATF4 to alleviate hypoxia in vivo [81] [83] [110, 111]. Transformed 
Kras MEFs expressing a mutant eIF2" variant give rise to tumors with high levels 
of cell death in hypoxic regions [110, 111].  In comparison, transformed wild type 
&(
MEFs give rise to larger tumors with less cell death in hypoxic tumor regions. 
Sectioning of wild type and mutant tumors correlated lack of ATF4 expression 
with increased sensitivity to hypoxia, accounting for the 80% of apoptotic cells 
found in hypoxic regions of eIF2" mutant cells versus only 17% in eIF2" wild 
type tumors [110]. This suggests that ATF4 promotes cell survival in hypoxic 
regions.  
The ability of cancer cells to survive in regions of hypoxia leads to the 
selection of increasingly resistant cells. ATF4 further promotes chemotherapeutic 
drug resistance by binding to the ATF-CRE like sequence in SIRT1’s promoter 
[130]. Increased SIRT1 expression leads to increased expression of ABC 
transporters that selectively pump chemotherapy drugs out of cells [131]. This 
reduces chemotherapy concentration inside the cell, decreasing drug efficacy 
[133]. 
ATF4 not only increases survival in hostile environments while increasing 
drug resistance, it also promotes survival during metastasis, allowing cells to 
leave unfavorable surroundings. Loss of attachment in non-transformed cells 
triggers anoikis, a mitochondrial mediated apoptotic response, and increases 
ROS [113]. Fibrosarcomal and colorectal adenocarcinoma cancer cells 
circumvent this by using PERK to increase ATF4 levels. ATF4 binds to the 
antioxidant response element in heme oxygenase 1 (HO-1), an antioxidant gene, 
driving a five-fold increase of HO-1, decreasing ROS mediated damage and 
death [113]. Conversely, knockdown of ATF4 decreases survival during loss of 
&)
attachment as cells are unable to induce expression of HO-1 [113]. This was 
substantiated in a lung cancer colonization mouse models in which ATF4 
knockdown inhibited colonization and tumor formation in all mice tail vein injected 
with human fibrosarcoma cells [113]. Conversely, lung colonization and tumor 
formation resulted in 6 of 7 mice tail vein injected with ATF4 wild type human 
fibrosarcoma cells [113].  This suggests that ATF4 promotes survival of cells as 
they are transported in the vasculature, increasing naïve tissue colonization. Of 
utmost importance, Kaplan Meier curves generated via the Georgetown 
Database of Cancer correlated increased levels of HO-1 with decreased survival 
rates of GBM patients [113]. This same trend was also found in lung cancer 
patients, with increased HO-1 expression correlating with decreased survival 
[113]. As GBMs have increased ATF4 expression, it is very possible that ATF4 is 
a key factor in promoting tumor cell survival by increasing levels of amino acid 
synthesis, molecular chaperones, enzymes that degrade ROS, transporters 
resulting in drug efflux, as well as increased survival in response to hypoxia while 
mediating protective autophagy.  
If the stress is resolved, then the ER stress-signaling cascade needs to be 
de-activated. ATF4 mediates this aspect of the ER stress response by increasing 
BiP and GADD34 levels [76] [125] [128]. As BiP accumulates in the ER, it binds 
to the luminal domain of PERK, turning the kinase off [39]. ATF4 reverses the 
PERK-induced translational block induced by eIF2" phosphorylation by binding 
to its consensus sequence in the GADD34 promoter. GADD34 activates PPI, 
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type 1 protein serine/threonine phosphatase, which de-phosphorylates eIF2", 
reinstating mRNA translation [77].  Turning off the ER stress response signaling 
pathway is just as important as turning it on. Mutant ATF4 MEFs are unable to 
induce GADD34 expression, resulting in prolonged eIF2" phosphorylation and 
decreased recovery in response to ER stress [77].  
ATF4 Summary 
ATF4 promotes the survival of cancer cells in deleterious environments. 
However, its prolonged expression can lead to induction of the pro-apoptotic 
transcription factor CHOP. As cancer cells are dependent on ATF4 to mitigate 
ER stress, it is possible to exploit this weakness by forcing even more ATF4 
expression in response to drug induced ER stress [10] [39]. This would tip the 
balance between the pro-survival and pro-death ER responses to favor one of 
pro-death.  Exacerbating ER stress to induce death has been validated in vitro 
with the ER stress inducing agents THAP and TUN; however, these drugs cannot 
be used in the clinic because of high toxicity and off target effects [10] [81] [83]. 
We have found that the novel ER stress- inducing agent, JLK1486, when used in 
combination with TMZ, induces ER stress and sustains ATF4 expression over an 
extended time course, resulting in CHOP mediated apoptosis [19]. 
CHOP 
CHOP identification and function   
 GADD153, growth arrest and DNA damage inducible protein 153, was one 
of twenty novel transcripts identified in the late 1980’s to increase in response to 
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UV DNA damage [132]. As GADD153 was localized to the nucleus it suggested 
that it regulated transcription [124] [133]. Later studies confirmed that GADD153 
encodes the CAAT/EBP homologous protein known as CHOP [127] [134]. 
CHOP is a bZIP transcription factor comprised of a basic DNA-binding 
domain and a leucine zipper motif that facilitates the formation of homo and 
heterodimers [127]. Similar to ATF4, CHOP can act as either a repressor or an 
activator depending on its binding partner. For example, CHOP dimerization with 
C/EBP transcription factors blocks binding to classical C/EBP consensus 
sequences, repressing transcription of genes normally activated by C/EBP 
homodimer formation [127]. Conversely, ATF3 and CHOP heterodimers prevent 
ATF3 from binding to c/AMP sites, resulting in activation of genes that ATF3 
normally represses [127].   
CHOP itself is regulated by cis-acting elements in its promoter. Its C/EBP 
binding site is recognized by C/EBP #, which induces CHOP [127]. As CHOP 
accumulates, it dimerizes with C/EBP #, preventing C/EBP # from binding to its 
own promoter, resulting in decreased transcription of itself [127].  
CHOP induction is tightly regulated. There is low to undetectable mRNA 
levels in non-damaged cycling cells, suggesting CHOP expression inhibits 
proliferation [135]. Indeed, it was found that CHOP induces cell cycle arrest and 
apoptosis when ectopically expressed [137[136]. For instance, forced expression 
of CHOP in HeLa or 3T3 cells results in 90% reduction of BrdU incorporation, 
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suggesting that CHOP inhibits DNA synthesis during S phase [136]. This is 
advantageous as it ensures that only unstressed, undamaged cells propagate. 
 It was suggested that CHOP expression prevents damaged cells from 
entering the cell cycle, preserving genomic integrity. Supporting this, CHOP wild 
type versus mutant cells have a 60% decrease in BrdU incorporation in response 
to serum starvation [136]. When starved cells are stimulated with complete 
media, the cells undergo a G1/S arrest, confirming that CHOP blocks stressed 
and damaged cells from entering the cell cycle [136]. In order to do so, CHOP is 
expressed in early G1 [136]. A G1 arrest allows cells to repair DNA damage 
before entering the cell cycle, preventing the loss of genetic material during sister 
chromatid separation. Mutations in either the basic domain or leucine zipper of 
CHOP results in loss of G1/S arrest, suggesting that CHOP must recognize DNA 
and form functional dimers to prevent cell cycle progression [136]. The 
importance of CHOP preventing aberrant cells from cycling is evident in myxoid 
liposarcoma cancer cells. These cells express a fusion protein of CHOP with a 
RNA binding protein, rendering CHOP inactive [136]. As a result, myxoid 
liposarcoma cells are unable to initiate a G1/S arrest, facilitating the propagation 
of these cancer cells, highlighting the vital role CHOP mediates in protecting 
genomic integrity [136]. 
CHOP responds to ER stress triggers 
 Although initial work suggested CHOP solely responds to DNA damage, 
others found amino acid and glucose deprivation as well as ERSA treatment also 
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induced CHOP [127] [137]. More puzzling, UV irradiation of keratinocytes only 
resulted in a slight induction of CHOP, quite the opposite of the study that first 
identified CHOP as an important factor of DNA damage response in CHO cells 
[137]. Surprisingly, exposure of keratinocytes to metabolic insults significantly 
increased CHOP levels [137]. Taken together, the data suggests that CHOP 
induction occurs in response to alternative environmental cues not linked to DNA 
damage.  
 It was later found that the cells used in the initial report linking CHOP 
induction to DNA damage were cultured under nutrient deprived conditions [136, 
137]. As nutrient deprivation induces ER stress, resulting in CHOP induction, it 
was suggested that its induction was the result of ER stress, not DNA damage. 
To verify this, the initial experiment was repeated with the same experimental 
conditions; however, protein was collected before and after UV exposure. CHOP 
was significantly elevated before UV exposure, but it was further increased in 
response to UV, suggesting that UV exposure exacerbated the response to the 
nutrient stressed environment [137].  This demonstrated that CHOP responds to 
both DNA damage and ER stress, preventing aberrant cells or those in 
unfavorable conditions from propagating.  
CHOP expression is regulated by the ER stress response 
CHOP is the ER stress effector that induces cell death [75]. How the ER 
stress response pathway regulated CHOP expression was unknown until 
sequence analysis revealed the presence of an ER stress response element 
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(ERSE) in its promoter [126].  This was important because many mammalian 
chaperone genes involved in the ER stress response have the 5’ CCAAT-9bp-
CCAGC3’ sequence, with at least one GGC triplet in the 9 base pair region 
separating the 5’ from 3’ end [126]. Indeed, it was found that ATF6 bound to 
CHOP’s ERSE in response to amino acid deprivation and induced its expression 
when TFII-1 was associated with CHOPs GGC triplet [126]. Validating this, 
mutations in CHOP’s ERSE sequence in CHO cells reduced CHOP expression, 
suggesting that CHOP may be regulated in response to ER stress [126]. 
However, as CHOP induction was only reduced, not blocked, in response to 
ERSE mutation, it suggested other factors with non-ERSE dependent binding 
domains also regulated its expression [126]. 
Interestingly, increased CHOP expression did not occur in ERSA-treated 
cells until ATF4 protein levels accumulated [126, 127]. This suggested ATF4 may 
directly or indirectly regulate CHOP expression. To delineate a PERK-ATF4- 
CHOP pathway, PERK deficient MEFs were treated with THAP and assayed for 
ATF4 and CHOP induction. However, PERK deficient cells were unable to induce 
either factor [81] [83]. Transfection of ATF4 in PERK deficient THAP treated 
MEFs rescued CHOP expression, suggesting ATF4 acts as an upstream 
regulator of CHOP [81] [83]. Expression of a mutant ATF4 lacking its N terminal 
activation domain in PERK deficient MEFs was unable to induce CHOP, 
corroborating an ATF4 mediated CHOP regulation [81] [83]. The identification of 
a C/EBP-ATF composite site in CHOP’s promoter validated the observed link 
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between ATF4 and expression and CHOP induction [126, 127].  Although CHOP 
is only observed after accumulation of ATF4 protein, ATF4 alone is unable to 
induce expression of CHOP. In order to increase CHOP expression in response 
ERSAs, ATF4 must form a heterodimer with C/EBP # [126, 127]. In fact, ATF4-
C/EBP # complexes are only found at CHOP’s promoter after treatment with 
THAP, and deletion of either the ATF site or the C/EBP consensus site inhibits 
ATF4 mediated CHOP expression [126]. This suggests that ATF4 increases 
CHOP expression, that it must be bound to C/EBP # to do so, and that both ATF-
C/EBP consensus sites are required for CHOP induction. This again points to the 
tight regulation of genes through ATF4 heterodimerization and how induction of 
CHOP cannot occur until elevated levels of ATF4 accumulate, giving the cell time 
to recover from ER stress and hostile environments before initiating cell death.  
CHOP induction promotes cell death 
ERSA treatment of pancreatic and glioma cancer cell lines increases 
CHOP expression, resulting in caspase 3 activation and cell death [95] [137]. 
Cisplatin, a cross linking agent, induces apoptosis in HeLa cells due to increased 
calcium efflux from the ER [138].  Glioma cells treated with desipramine, a 
tricyclic antidepressant, have increased CHOP levels correlating with increased 
caspase 3 and 9 cleavage, resulting in apoptosis [139].  Treatment of glioma and 
breast cancer lines with TZD18, the ligand for the peroxisome proliferating 
receptor, induced ER stress, resulting in decreased cell growth and increased 
cell death [140]. Amiodarone, an antiarrythmic drug, increased ATF4 and CHOP 
'&
levels, resulting in apoptosis when combined with TRAIL in glioma cells [141]. 
Minocycline, a derivative of tetracycline that works as a bacteriostatic agent, 
induces ER stress, increasing P EIF2 alpha, CHOP, and spliced XBP in glioma 
cells, leading to apoptosis [142].  Although these, and a myriad of other drugs, 
effectively harness the ER stress response to induce cell death, it is important to 
understand how the ER pathway uses CHOP to initiate cell death.  
Increased CHOP expression precedes ER stress induced cell death; 
however, the question remains whether CHOP itself induces cell death or CHOP 
is an ER stress marker prefacing cell death.  To determine if CHOP mediates ER 
cell death, a CHOP deficient mouse model was generated. CHOP deficient mice 
are viable and fertile, demonstrating that CHOP is not required for development 
as no major abnormalities were detected [138].  Both CHOP wild type and 
deficient MEFs induced BiP in response to ER stress, demonstrating that CHOP 
is not required for the initial ER stress response [138]. However, CHOP deficient 
MEFs treated with ERSAs were resistant to cell death. Wild type MEFs balled up 
and detached from substratum in response to ERSAs, resulting in an almost 
100% cell death after 48 hours of treatment [138]. Conversely, CHOP deficient 
MEFs remained attached to the plate and only exhibited a 50% reduction in cell 
viability at 48 hours post treatment [138]. This was validated as CHOP deficient 
TUN treated MEFs had a 3 to 5 fold increase in colony formation versus wild type 
MEF TUN treated cells, showing loss of CHOP correlates with increased viability 
[138]. Injection of sublethal doses of TUN in CHOP deficient mice resulted in 
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decreased cell death as well as reduced swelling of proximal tubular epithelium 
cells in the kidney compared to wild type mice, suggesting that CHOP knockout 
mice had decreased cell death [138] [143]. As CHOP was determined to play a 
vital role in ER stress death, the next question became how CHOP executed this. 
CHOP activates the intrinsic cell death pathway 
CHOP mediated ER cell death involves both intrinsic and extrinsic 
apoptotic pathways. The Bcl-2 family has 20 plus members and controls the 
intrinsic apoptosis pathway [84].  The Bcl-2 family includes three subsets: anti-
apoptotic, pro-apoptotic, and BH3 only. The anti-apoptotic members, including 
Bcl-2 itself, Bcl-xl, Bcl-w, and A1, inhibit the activity of pro-apoptotic members 
BAX, BAK, and BOK, as well as BAD, BID, BIK, BIM, PUMA, and NOXA, which 
belong to the BH3 only pro-apoptotic subdivision. Both pro and anti apoptotic Bcl-
2 family members localize to the ER membrane where they either directly or 
indirectly interact with two pumps that regulate calcium efflux and influx [84].   
The sarco/ER calcium ATPase pump, SERCA, imports calcium from the 
cytosol into the ER while the inositol triphosphate receptor, IP3R, releases 
calcium from the ER into the cytosol [84].  Regulating calcium efflux and influx is 
essential for maintaining ER homeostasis and mitochondrial function.  If a flood 
of calcium is released from the ER, it is absorbed by nearby mitochondria. 
Calcium absorption inhibits the mitochondrial respiration chain, ultimately 
triggering release of cytochrome C from the mitochondrial outer membrane, and 
activating the caspase apoptosis pathway [84]. Although some evidence 
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suggests that Bcl-2 regulates SERCA, more convincing data suggest it interacts 
with IP3R, inhibiting release of calcium from the ER, reducing activation of 
mitochondrial mediated apoptosis [84]. Increased expression of the pro-apoptotic 
member BAK inhibits Bcl-2 and Bcl-xl from localizing to the ER membrane, 
preventing their interaction with SERCA or IP3R, resulting in calcium efflux from 
the ER [84].  BAX exacerbates BAK calcium efflux by forming homo oligomer 
pores in the outer membrane of the mitochondria, stimulating cytochrome C 
release [84] [86]. As calcium efflux and influx is regulated by both Bcl-2 pro and 
anti-apoptotic family members, it is easy to envision how changes in pro to anti- 
apoptotic ratios would either inhibit or promote ER stress induced death [84].
Analysis of CHOP over-expressing cell lines show that increased CHOP 
expression results in decreased mRNA and protein levels of Bcl-2 [84] [144]. This 
inverse relationship was corroborated as CHOP deficient MEFS were unable to 
decrease Bcl-2 levels when treated with ERSAs [145]. CHOP rescue in MEF 
deficient lines restored the inverse relationship in response to ERSAs, with 
increased CHOP levels resulting in decreased Bcl-2 levels. Further 
substantiating this, use of a Bcl-2 CAT reporter showed increased CHOP levels 
correlated with decreased reporter levels, indicating CHOP repression of Bcl-2 
transcription during ER stress [145].  Mutation of CHOP’s leucine zipper domain 
resulted in loss of transcriptional repression of the Bcl-2 CAT reporter, showing 
that CHOP regulates Bcl-2 expression and must form a functional dimer to do so 
[145].  Additional experiments suggest CHOP represses Bcl-2’s promoter, 
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shifting the anti-apoptotic ratio to favor pro-apoptotic factors [86]. Shifting 
expression would promote cell death as Bcl-2 levels would be too low to inhibit 
pro-apoptotic factors. If this is indeed the mechanism, then over expression of 
Bcl-2 in CHOP over expressing lines would prevent ER stress induced death.  
Over expression of Bcl-2 in CHOP over expressing lines led to a four-fold 
decrease in cell death in response to THAP or TUN treatments, suggesting that 
CHOP decreases Bcl-2 levels in response to prolonged ER stress [145]. 
When Bcl-2 levels decrease, pro-apoptotic factors initiate cell death as 
Bcl-2 anti-apoptotic members no longer inhibit them [84] [86]. To this extent, 
CHOP may promote cell death by both transcriptionally repressing Bcl-2 and 
increasing Bcl-2 pro-apoptotic family members. TUN treatment increases CHOP 
levels, leading to increased expression of pro-apoptotic BH3 members, PUMA 
and BIM [135]. In response to ER stress, PUMA and BIM bind to Bcl-2, 
neutralizing it, resulting in release of cytochrome C from the mitochondria due to 
permeabilization of the outer membrane mediated by pro-apoptotic members 
BAX and BAK [135]. Data suggests CHOP increases BIM transcription and binds 
to PUMA’s promoter during ER stress; however, the factors that promote this 
binding and subsequent up-regulation remain to be identified. A potential 
candidate is FOXO3a, a member of the forkhead transcription factor family 
regulated by the PI3K/AKT survival signaling cascade [135]. When AKT is active, 
FOXO3a is phosphorylated, preventing it from translocating to the nucleus to 
increase expression of genes associated with apoptosis and cell cycle arrest [4].  
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As FOXO3a has been implicated in regulating PUMA transcription, it was asked 
if CHOP and FOXO3a interact. CHOP and FOXO3a interaction, as shown by co-
immunoprecipitation, was only detected in nuclear lysates of TUN treated cells, 
demomstrating that the two factors do interact [135]. Interestingly, TUN treatment 
of CHOP knockdown cells decreases PUMA expression with little to no BIM 
induction and cell death, and results in sustained PI3/AKT mediated FOXO3a 
phosphorylation and sequestration [135]. Although the model is speculative, it is 
tempting to suggest that CHOP may negatively regulate the PI3K/AKT axis in 
response to ER stress, resulting in FOXO3a translocation and association with 
CHOP to drive PUMA expression and promote cell death.  This is an attractive 
model as it suggests CHOP mediates ER stress and PI3K/AKT survival pathway 
crosstalk, allowing cells to properly respond to unfavorable environmental cues. 
CHOP activates the extrinsic cell death pathway  
Although the intrinsic pathway is primarily used to mediate and initiate ER 
stress induced cell death, the extrinsic pathway also contributes through 
activation of the death receptor pathway. When the tumor necrosis factor-related 
apoptosis inducing ligand, TRAIL, binds to death receptor 4 (DR4) or death 
receptor 5 (DR5), FASS-associated protein with death domain (FADD), is 
recruited to the receptors, serving as a platform for pro-caspase 8 and 10 binding 
[85] [87]. Pro-caspase 8 is cleaved, cleaving pro-caspase 10, which, in turn, 
activates the caspase signaling cascade, ending with cleavage of the effector 
caspase 3 [95]. Although TRAIL is expressed in many cancer cells lines, it is 
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unable to induce apoptosis as cancer cells amplify death decoy receptors and 
decrease DR5 [87]. Drugs that upregulate DR5 might re-sensitize cancer cells to 
TRAIL mediated death. Treatment of glioma cells with ER stress agents such as 
MG132, a proteasome inhibitor, or arsenic trioxide, which induces apoptosis in 
leukemia cells, increases expression of CHOP and DR5 [88] [145]. Importantly, 
increased expression of CHOP preceded enhanced DR5 expression. Both 
mutant and CHOP knockdown lines are unable to increase DR5 in response to 
arsenic trioxide, suggesting CHOP regulates DR5’s increase in response to ER 
stress [146]. CHOP transcriptional regulation of DR5 was validated through DR5 
reporter assays in which mutation of CHOP’s DNA binding site led to a more than 
3 fold decrease in DR5 driven luciferase [87] [146]. A variety of other ER stress 
inducing agents, such as caspaicin, amiodarone (anti-arrythmia drug), nelfinavir 
(FDA approved HIV protease inhibitor), MK886 (lipooxygenase inhibitor), 
confirmed the CHOP mediated upregulation of DR5. This led to the combination 
of ER drugs with TRAIL to significantly increase cell death [87] [143] [147,[147].  
For example, glioma cells treated with amiodarone and TRAIL results in only 
30% viability post treatment, suggesting TRAIL and ER stress inducing drugs are 
an advantageous means to increase death [143]. 
CHOP interferes with wnt, IL-6, and increases ROS to promote cell death 
 The majority of studies emphasize CHOP mediated cell death through 
activation of extrinsic and intrinsic apoptotic pathways; however, it is important to 
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note that CHOP also induces cell death by blocking pro-survival signals and 
exacerbating the response to ER stress conditions.  
 Recent data suggests that CHOP contributes to cell death by decreasing 
activation of the wnt pathway, resulting in decreased translocation of beta catenin 
[148]. Although the mechanism remains to be elucidated, there is precedent for 
CHOP mediated down regulation of wnt, the ligand responsible for frizzled 
receptor activation, in xenopus laevis embryos [149].  
 In addition to blocking survival signals transmitted by wnt, increased 
CHOP expression represses expression and secretion of interleukin 6 (Il-6) [26]. 
This may have therapeutic application as GBM cells, specifically EGFR VIII cells, 
increase IL-6 signaling to stimulate nearby endothelial cells, leading to the 
formation of larger, faster growing tumors [26].  Treatment of GBM cells with 
genistein increases expression of CHOP mRNA and protein, leading to the 
formation of CHOP-C/EBP # heterodimers [26]. This is problematic as CHOP-
C/EBP # heterodimers prevent C-EBP # from binding to IL-6, resulting in 
decreased IL-6 expression and secretion. This would decrease stimulation of 
endothelial cells and result in smaller tumors, as seen in VIII genistein treated 
mice [26]. 
Lastly, CHOP exacerbates ER stress by increasing the translation of 
mRNAs in an already stressed and overwhelmed ER [144] [149].  CHOP wild 
type MEFs versus mutant CHOP MEFs increase GADD34 expression, which 
leads to the de-phosphorylation of eIF2A, alleviating the repression of mRNA 
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translation, while increasing oxidative stress [144] [150]. Reversing translational 
repression benefits cells recovered from ER stress and ready to resume cell 
processes. It is detrimental to cells that have not yet re-established ER 
homeostasis, thereby tipping the scale towards cell death. 
GBM cells evade CHOP mediated cell death 
 GBMs evade CHOP mediated cell death by interfering with the activation 
of the extrinsic and intrinsic apoptotic pathways.  To prevent pro-apoptotic Bcl-2 
family members from initiating apoptosis, GBM cells increase expression of pro-
survival Bcl-2 factors, including Bcl-2 itself and Bcl-xl [87]. Moreover GBM cells 
repress expression of pro-apoptotic Bcl-2 members, ensuring that the ratio of 
pro-survival to pro-apoptotic factors is always in favor of survival, decreasing the 
ability of pro-apoptotic member from initiating mitochondrial mediated apoptosis 
[3].  Furthermore, GBM cells have constitutively active PI3K/AKT signaling due to 
mutation of the tumor suppressor gene, PTEN, which negatively regulates the 
axis [1] [20] [22]. As previously addressed, AKT signaling inhibits translocation of 
FOXO3a, leading to decreased CHOP-FOXO3a heterodimer formation, resulting 
in decreased transcription of the pro-apoptotic member, PUMA [135]. GBM cells 
further avoid CHOP induced cell death by increasing expression of death decoy 
receptors on their surface [87]. This reduces TRAIL mediated activation of DR5, 
resulting in decreased induction of the extrinsic cell death pathway. 
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Summary 
The ER stress pathway initially promotes a pro-survival response by stalling 
mRNA translation, and increasing the synthesis of amino acids, molecular 
chaperones, and enzymes to facilitate protein folding [10] [39]. However, if stress 
cannot be resolved, the pro-survival response switches to pro-death [75]. This is 
due to sustained ATF4 expression inducing transcription of the pro-apoptotic ER 
transcription factor, CHOP [95] [138] [145]. It is possible to force the pro-survival 
to pro-apoptotic switch by exacerbating ER stress with the use of drugs, such as 
JLK1486 [35] [39]. This is an attractive approach as GBMs rely on the ER to 
mitigate their unfavorable environment. Following this strategy, we found that 
addition of JLK1486 to TMZ not only forced this switch, but also impaired cells 
ability to resolve DNA DSBs, leading to increased cell death [19]. Our data 
suggests the use of ER stress inducing agents may provide an added benefit 
when combined with TMZ and should be further explored. 
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CHAPTER II 
Rationale of drug combination  
We tested if the addition of JLK1486, a novel ER stress- inducing agent, to 
TMZ, a DNA alkylating agent, increased the efficaciousness of therapy. We 
reasoned that formation of DNA DSBs occurring in the presence of an 
overwhelming ER stress response would be catastrophic to cell survival.    
Results 
JLK1486 is active as a single agent 
 To determine the efficacy of JLK1486 as a single agent, we utilized a 
panel of GBM adherent, non-adherent, and primary lines.  For the majority of our 
established adherent GBM lines, a low concentration of JLK1486 inhibited 
proliferation (Figure 3A-E; U87MG IC50= 0.6 µM; A172 IC50 = 0.26 µM; 
U118MG IC50 = 0.87µM; LN18 IC50 = 0.27 µM); however, one line, T98G, was 
relatively resistant to JLK1486 (Figure 3D; T98G IC50 = 7.6 µM). To assess the 
efficacy of JLK1486 in both converted non-adherent and primary lines, we 
employed neurosphere assays in which spheres are dissociated, single cells are 
plated at clonal density, drug treated, and allowed to grow. On either the seventh 
(converted non-adherent cell lines) or tenth day (primary cell lines), 
neurospheres, defined as a single sphere containing ten or more cells, were 
counted to measure the effects increasing concentrations of JLK1486 had on 
growth. We found our two converted non-adherent cell lines, U87NS and 
U118NS, were sensitive to JLK1486 (Figure 3F-G; U87NS IC50 = 1.6 µM; 
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U118NS IC50 = 0.13 µM).  Our primary lines, GS8-26 and 5075, were also 
sensitive to JLK1486, with an IC50 of 0.08 µM in both lines (Figure 3 H-I).
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JLK1486 combined with TMZ reduces secondary sphere formation more 
effectively than JLK1486 or TMZ as single agents 
Secondary sphere formation assays are an in vitro tool to mimic the 
clinical recurrence universally exhibited in GBM patients, allowing one to monitor 
self-renewal and durability of treatment. Additionally, non-adherent cells form 
more infiltrative tumors than established, adherent cell lines, such as U87MG 
cells, and are therefore a better representation of clinical GBMs [93]. Non-
adherent cell lines are dissociated, plated at clonal densities, drug treated and 
allowed to grow for seven or ten days. Fresh medium is added on day seven 
(U87NS, U118NS) or ten (GS8-26, 5075), and cells are allowed to grow an 
additional seven (U87NS, U118NS) or ten (GS8-26, 5075) days, and then 
counted, allowing cell and sphere recovery to be assessed. On day fourteen 
(U87NS, U118NS) or day twenty (GS8-26, 5075), spheres are dissociated to 
single cells, re-plated, allowed to grow for an additional seven (U87NS, U118NS) 
or ten days (GS8-26, 5075), and then counted to assess secondary sphere 
formation (Figure 4; Figure 5 A-B). 
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To determine if JLK1486 as a single agent blocked secondary sphere 
formation, we carried out a neurosphere formation assay with U87NS cells using 
a range of JLK1486 doses from 0µM to 20µM. Although JLK1486 alone at the 
IC50 for U87NS (2µM) (Figure 6A) did not completely block secondary sphere 
formation, there was a statistically significant reduction of day 21 secondary 
spheres compared to the DMSO control sample.  A higher dose of JLK1486 
(20µM, ten times higher than the IC50) completely blocked secondary sphere 
formation (Figure 6A).  Reduced sphere formation suggests that JLK1486 may 
be a novel chemotherapeutic for delaying recurrence. 
This led us to ask if the efficacy of TMZ, the chemotherapeutic agent 
currently used in the clinic, could be improved if used in combination with 
JLK1486. We performed secondary sphere formation assays using TMZ alone 
(the relevant dose of TMZ in our converted non-adherent lines has been 
previously described [150]) and in combination with a sub-IC50 dose of JLK1486 
(1µM) as well as the IC50 dose (2µM) in U87NS cells (Figure 5C).  We did not 
find a statistically significant reduction of secondary spheres for the sub-optimal 
dose of TMZ+ 1µM JLK1486 when compared to TMZ alone (Figure 6B).  We did 
find significant reduction of secondary sphere formation in TMZ+ 2µM JLK1486 
versus TMZ or JLK1486 alone (Figure 6B). However, there was not a complete 
block in secondary sphere formation in the TMZ+2µM JLK1486 dose, indicated 
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by the statistically significant increase in sphere formation in day 14 versus day 
21 samples (Figure 6B). 
In the clinic GBM patients receive multiple doses of chemotherapeutics [5] 
[34]. We asked if two doses of JLK1486 would increase the efficaciousness of 
the TMZ+JLK1486 combination treatment. We carried out secondary sphere 
formation assays in which cells were dosed with TMZ+JLK1486 on day 0 and 
then treated a second time with JLK1486 alone on day 7 (Figure 5D). Because 
the pharmacokinetics, mechanism, and durability of TMZ treatment have been 
established and shown to occur up to 120 hours, we reasoned that substantial 
TMZ induced DNA damage would have occurred by day 7 and that a second 
dose of JLK1486 on day 7 may exacerbate the TMZ induced damage [29] [33]. 
We found significant secondary sphere reduction in the sub-optimal dose 
combination of TMZ+ 1µM JLK1486 2X versus TMZ+ 1µM JLK1486 1X  (Figure 
6C versus Figure 6B) as well as inhibition of secondary sphere formation in 
TMZ+ 2µM JLK1486 2X versus TMZ+ 2µM JLK1486 1X  (Figure 6C versus 
Figure 6B). Additionally, we found significantly decreased secondary sphere 
formation in our converted non-adherent U118NS line as well as our primary 
lines GS8-26 and 5075 when cells were treated on day 0 with TMZ+ JLK1486 
and a second time with JLK1486 on day 7 (Figure 6D-F). This demonstrates that 
the TMZ+ JLK1486  is an effective combination therapy to decrease secondary 
sphere formation and may be a schedule-dependent process . All further 
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experiments were conducted using TMZ+JLK1486 2X (JLK1486 on day 0 and on 
day 7; figure 5D). 
 
 
)#
 
TMZ+JLK1486 treatment results in decreased cell growth and increased 
cell death in U87NS 
To determine how TMZ+2µM JLK1486 treatment reduced secondary 
sphere formation in U87NS cells, we carried out a time course ranging from 24 
hours to 23 days to evaluate the number of trypan blue positive and negative 
cells.  Control cells treated with DMSO had the highest rate of proliferation from 
day 0 to day 14 (Figure 7A). Cells treated with either 1µM or 2µM JLK1486 
increased in number from day 0 to day 14, however, there were significantly 
fewer JLK1486-treated cells versus the DMSO control (Figure 7A). Cells treated 
with either TMZ alone or TMZ in combination with 1µM or 2µM JLK1486 did not 
undergo significant proliferation from day 0 to day 14  (Figure 7A). This was 
expected as it has been well established in the literature that TMZ induces DNA 
double strand breaks that result in G2/M arrest. After day 14 dissociation and re-
plating, DMSO, 1µM and 2µM JLK1486-treated cells, as well as TMZ alone 
treated cells underwent significant proliferation from day 16 to day 23 (Figure 7A-
B). Although the number of TMZ+1µM JLK1486- treated cells was less than TMZ 
alone treated cells on day 23, this was not statistically significant (Figure 7B). 
However, cells treated with TMZ+2µM JLK1486 were incapable of repopulating 
their cultures and maintained a statistically significant reduction in cell number 
versus JLK1486 alone as well as TMZ alone (Figure 7B). This suggests that 
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inhibition of secondary sphere formation in TMZ+2µM JLK1486-treated cells is at 
least partly the result of treated cells’ inability to proliferate. 
We simultaneously collected trypan-blue-positive counts to detect cell 
death in U87NS control, single agent, and TMZ+JLK1486-treated cells.  We 
observed significant increases in cell death in TMZ alone as well as TMZ+1µM 
JLK1486 and TMZ+2µM JLK1486-treated cells versus DMSO and 1µM and 2µM 
JLK1486 single-treated cells in the first half of our time course (Figure 7C; days 
0-14). However, post day 14, we observed a significant decrease in the 
percentage of trypan blue positive cells from day 16 to day 23 in TMZ alone 
treated cells (Figure 7C). Although the percentage of trypan-blue-positive 
TMZ+1µM JLK1486 cells also decreased for samples post day 14, the percent 
remained significantly higher than TMZ or 1µM JLK1486 alone (Figure 7C). 
Conversely, the percent of trypan-blue-positive cells in TMZ+2µM JLK1486-
treated cells continued to increase post day 14 (Figure 7C). This resulted in a 
70.0% (+/- 5.0) trypan-blue-positive population in TMZ+ 2µM JLK1486-treated 
cells versus 14.3% (+/- 3.2) in TMZ-treated cells and 10.3% (+/- 3.9) in 2µM 
JLK1486-treated cells (Figure 7D).  
To test if the observed increase in cell death was due to apoptosis, we 
performed FACS analysis with annexin V and propidium iodide (PI) staining of 
23-day samples. The annexin V and PI staining corroborated our trypan blue 
counts as we observed 70.6% double positive cells in TMZ+2µM JLK1486-
)%
treated cells versus 3.9% in DMSO, 2.6% in 2µM JLK1486 alone, and 2.3% in 
TMZ alone treated cells (Figure 7 E-H;I-J).  
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 This demonstrates that TMZ+ 2µM JLK1486 treatment in U87NS cells 
results in reduced cell growth due to the induction of apoptosis.   
TMZ+JLK1486 treatment induces prolonged endoplasmic reticulum stress 
that results in induction of CHOP, a pro-apoptotic transcription factor 
It is well established that prolonged, unresolved ER stress triggers 
apoptosis [151-153]. To determine if TMZ+2µM JLK1486 treatment results in 
prolonged ER stress induction, we collected a series of protein lysates over a 24-
hour to 23-day time course. We probed protein lysates for levels of BiP, a key 
heat shock molecular chaperone indicative of ER stress, as well as ATF4, a 
transcription factor that initially serves as a pro-survival signal but switches to 
pro-apoptotic when ER stress is unresolved. ATF4 drives increased expression 
of the pro-apoptotic transcription factor CHOP. We therefore analyzed protein 
lysates for ATF4 and CHOP to detect this switch. 
  In 2µM JLK1486 and TMZ+2µM JLK1486-treated cells we observed 
increased expression of BiP that was maintained 14 days post treatment 
suggesting that JLK1486 induces prolonged ER stress (Figure 8). For post 
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treatment day 14, BiP levels were highly elevated in all conditions (Figure 8). 
Increased expression of ATF4 was observed only in JLK1486 and TMZ+2µM 
JLK1486-treated cells (Figure 8). Induction began three days post treatment and 
was maintained 21 days post treatment, suggesting generation of long-term ER 
stress (Figure 8). We did find strong expression of ATF4 in day 14 DMSO-treated 
cells (Figure 8). We suggest this induction is due to nutritional deprivation 
resulting from these rapidly proliferating cells becoming overgrown. This is 
substantiated by a slight decrease in day 14 trypan blue negative cell number 
(Figure 7A) as well as the lack of increased and sustained CHOP induction of 
day 14, 19, and 21 DMSO versus 2µM JLK1486 alone or TMZ+2µM JLK1486-
treated samples (Figure 8). Induction of CHOP was not observed until 9 days 
post 2µM JLK1486 and TMZ+2µM JLK1486 treatment (Figure 8). CHOP levels 
were maintained until day 14 in 2µM JLK1486 alone and TMZ+ 2µM JLK1486-
treated cells.  Increased CHOP expression was detected in TMZ+ 2µM JLK1486-
treated cells in day 19 and day 21 lysates (Figure 8).  ATF4 and CHOP were 
undetectable in all day 23 protein lysates (Figure 8). Induction of BiP and ATF4 in 
2µM JLK1486 and TMZ+ 2µM JLK1486-treated cells suggests that JLK1486 is 
an effective ER stress-inducing agent and may promote cell death via prolonged 
ATF4 expression driving CHOP in TMZ+ 2µM JLK1486-treated cells. 
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TMZ+JLK1486 treatment triggers prolonged activation of DNA damage 
response pathway and promotes unresolved DNA double stand breaks 
TMZ induces the formation of DNA DSBs. This results in phosphorylation 
of DNA damage transducers, ATM and CHK2, which in turn induces 
phosphorylation of H2A.X, a key marker for DSBs, and recruitment of RAD51 to 
DSBs to initiate homologous recombination [154-156]. To determine if the 
combination of TMZ+2µM JLK1486 increases and/or prolongs DNA damage, we 
analyzed a series of protein lysates collected from 24 hours to 23 days post 
treatment for P ATM, ATM, P CHK2, CHK2, RAD51, and !H2A.X.  
We observed phosphorylation of ATM and CHK2 24 hours post treatment 
in TMZ and TMZ+2µM JLK1486-treated cells (Figure 9).  Increased levels of P 
ATM and P CHK2 were maintained in TMZ and TMZ+2µM JLK1486-treated cells 
throughout the time-course, however, we noted higher levels of P ATM and P 
CHK2 in post day 14 combination lysates, suggesting TMZ+2µM JLK1486 
treatment results in a sustained DNA damage response (Figure 9). Additionally, 
we detected extended phosphorylation of H2A.X in TMZ+2µM JLK1486-treated 
cells, suggesting substantially more unresolved DNA DSBs in combination 
versus TMZ single treated cells (Figure 9; Figure 10). Although high levels of 
RAD51 were initially observed in all conditions, we found RAD51 levels 
decreased 5 days post treatment in 2µM JLK1486 alone and TMZ+2µM 
JLK1486-treated cells and were continually lower than TMZ alone treated cells 
until 21 days post treatment (Figure 9). Increased expression of RAD51 was not 
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detected until 23 days post treatment. Detection of increased P ATM, P CHK2, 
and prolonged !H2A.X in TMZ+2µM JLK1486 cells suggests that combination 
treatment not only prolongs the DNA damage response, but also promotes 
unresolved DNA DSBs over an extended time course through reduction of 
RAD51. 
Knockdown of ATF4 does not rescue secondary sphere formation but does 
decrease cell death in TMZ+JLK1486 treated cells 
Because we observed inhibition of secondary sphere formation (Figure 6), 
increased cell death (Figure 7) and prolonged expression of ATF4 in TMZ+2µM 
JLK1486- treated cells (Figure 8), we asked if knockdown of ATF4 would rescue 
secondary sphere formation and decrease cell death. To determine this, we 
generated three stable U87NS lines, one expressing an shRNA control, and two 
lines expressing shRNAs against ATF4, shATF4 C1 and shATF4 E7. The U87NS 
sh control, shATF4 C1, and shATF4 E7 lines were treated with DMSO, 2$M 
JLK1486, 200$M TMZ, and TMZ+2µM JLK1486, protein lysates were collected 
at 24 hours and five days post treatment, and ATF4 levels were examined via 
western. Because neurosphere and trypan blue assays were carried out with 
cells plated at passage four and assays completed by passage six, we analyzed 
ATF4 expression levels in our knockdown lines at passage number six to verify 
that knockdown was maintained throughout the experimental time-course. We 
observed robust induction of ATF4 in 2$M JLK1486 and TMZ+2µM JLK1486 sh 
control treated U87NS cells, slight induction of ATF4 in 2$M JLK1486 and  
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TMZ+2µM JLK1486 shATF4 C1 treated U87NS cells, and no expression of ATF4 
in 2$M JLK1486 and TMZ+2µM JLK1486 shATF4 E7 treated U87NS cells 
(Figure 11F).  
To determine if knockdown of ATF4 rescues secondary sphere formation, 
we treated our sh control, shATF4 C1, and shATF4 E7 U87NS lines with DMSO, 
2$M JLK1486, 200$M TMZ, and TMZ+2µM JLK1486 and carried out 
neurosphere assays. On day 21, we did not observe formation of secondary 
spheres in the U78NS sh control or in either of our U87NS shATF4 lines, C1 or 
E7, demonstrating that knockdown of ATF4 does not rescue secondary sphere 
formation in TMZ+2µM JLK1486-treated cells (Figure 11 A-C). 
As neurosphere assays may not evaluate the effect drug treatment has on 
viability, we determined if ATF4 knockdown decreased cell death in our U87NS 
sh control and shATF4 C1 and E7 lines by carrying out a time course of trypan 
blue counts. As increased cell death in U87NS TMZ+2µM JLK1486-treated cells 
was most significant at later time points (Figure 7), we focused on analyzing the 
number of trypan-blue-positive cells in our control and ATF4 knockdown lines at 
day 16, 19, and 21 time points.  Furthermore, because U87NS cells treated with 
TMZ alone had significant reduction in cell growth, but were able to repopulate 
the culture versus TMZ+ 2µM JLK1486-treated cells (Figure 7B), we were most 
interested in comparing the effects of ATF4 knock down in TMZ versus 
TMZ+2µM JLK1486-treated cells (all conditions shown in Figure 12).  
*$
We observed a statistically significant decrease in the number of trypan-
blue-positive cells in ATF4 knockdown versus sh control TMZ+2µM JLK1486-
treated cells at day 19 and day 21 (Figure 11D-E; Day 19: C1= 31%; E7= 24%; 
control= 53%) (Figure 11D-E; Day 21: C1= 32%; E7= 18%; control = 56%). 
Reduction of cell death in ATF4 U87NS knockdown cells treated with TMZ+2µM 
JLK1486 suggests ATF4 may play a role in promoting cell death in TMZ+2µM 
JLK1486-treated cells.  
To explore why ATF4 knockdown results in decreased cell death in 
TMZ+2µM JLK1486-treated cells, we analyzed levels of RAD51 in sh control 
versus shATF4 U87NS treated with DMSO, 2$M JLK1486, 200$M TMZ, and 
TMZ+2µM JLK1486. We analyzed lysates collected 24 hours and 5 days post 
treatment as we saw decreased expression of RAD51 in 2$M JLK1486 and 
TMZ+2µM JLK1486 U87NS treated cells at day 5 (Figure 9). Interestingly, we 
observed increased RAD51 levels in shATF4 knockdown lines versus sh control 
U87NS cells after 5 days of TMZ+2µM JLK1486 treatment (Figure 11F). This 
suggests a potential inverse relationship between ER stress induction of ATF4 
and RAD51 protein levels. 
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TMZ+JLK1486 treatment delays tumor doubling in vivo  
To determine if the combination of TMZ+JLK1486 is effective in vivo, we 
subcutaneously injected nude mice with U87NS cells, allowed tumors to form, 
and treated with DMSO, JLK1486 15mg/kg, TMZ 5mg/kg, or TMZ with JLK1486 
(Figure 13A).  We used time to tumor volume doubling as our readout to 
compare control, single agent, and double agent treated mice. 
We found significant delay in tumor doubling in JLK1486 versus DMSO   
(p = 0.0002), TMZ versus DMSO (p = 0.0005), TMZ versus JLK1486 (p = 
0.0007), TMZ+JLK1486 versus JLK1486 (p = 0.0003), and TMZ+JLK1486 versus 
TMZ alone (p = 0.04) treated mice (Figure 13B). This significant delay in tumor 
volume doubling for TMZ+JLK1486-treated mice suggests the combination 
should be further studied as it may have clinical applications.
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Conclusion 
We found that JLK1486 induces ER stress in GBM cells and when 
combined with TMZ, reduces proliferation. Decreased proliferation correlated 
with increased apoptosis. Interestingly, in combination treated cells, we observed 
decreased RAD51 expression, a key protein for repair of DNA DSBs.  We 
propose reduction of RAD51 levels as the mechanism that accounts for 
prolonged and unresolved DNA DSBs and increased apoptosis. Combination of 
JLK1486 with TMZ may provide a potential new chemotherapeutic regimen and, 
more intriguingly, may link unresolved ER stress with interference of DNA 
damage repair (Figure 14). 
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Materials and Methods 
Cell lines and cell culture reagents 
U87MG, A172, T98G, and LN18 cell lines were purchased from American Type 
Culture Collection (ATCC). U118MG cells were a kind gift from the laboratory of 
Dr. Larry Recht (Stanford University, Stanford, CA, 2003). Cell lines were verified 
via the Radil Idexx Cell Check (9 short tandem repeats) and maintained as 
monolayers in 10% FBS / DMEM (GIBCO; #11965-092) at 5% C02. 5075 and 
GS8-26 primary GBM lines were acquired from the UMASS tissue bank and 
maintained in defined medium DMEM/F12 1:1, 15mM/L HEPES, 1X B27 without 
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vitamin A, and supplemented with 20ng/mL bFGF and EGF [150].  The 
establishment of the primary line GS8-26 has been presented [150]. The 5075 
primary line was prepared in a similar procedure except Liberase instead of 
trypsin was used to digest the tumor [157]. U87NS and U118NS neurosphere 
lines were generated from adherent lines, maintained, and passaged as previous 
described [150].  
Reagents 
Temozolomide (T2577) was purchased from Sigma-Aldrich, re-suspended at 
10mg/mL in 100% DMSO, aliquoted, and stored at -20°C. The synthesis and 
structure of JLK1486 synthesis was previously described [158, 159]. JLK1486 
was re-suspended at 10mM in 100% DMSO, aliquoted, and stored at -20°C.  
MTS assay 
The IC50s’ of adherent lines was determined by plating 1X103 cells/100µL in 96 
well plates and after 24 hours treating the adherent cells with increasing 
concentrations of JLK1486 (0$M – 100$M).  Media was aspirated five days later 
and replaced with CellTiter 96 Aqueous One Solution Cell Proliferation Assay 
(MTS; Promega G35A) for ~3 hours. Plates were read at A490 nm. 
Primary and secondary neurosphere assays 
Neurosphere assays were carried out as previously described [160]. Briefly, 
U87NS, U118NS, GS8-26, and 5075 lines were pH dissociated, filtered (40 $m), 
plated at 6,000 cells /2mL in 6 well plates, and treated with DMSO, JLK1486, 
TMZ, or TMZ+JLK1486. Primary spheres were counted, fed, and dosed with 
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JLK1486 a second time on day 7 for U87 and U118 and on day 10 for primary 
lines GS8-26 and 5075. Sphere recovery was determined by counting spheres 7 
or 10 days later, day 14 for U87NS and U118NS and day 20 for primary lines. 
Spheres were then pH dissociated, diluted (U87NS, U118NS: DMSO=1:100; 
JLK1486= 1:50; TMZ= 1:1; TMZ+JLK1486=1:1; 5075, GS8-26: DMSO= 1:25; 
JLK1486= 1:2; TMZ= 1:2; TMZ+JLK1486= 1:1), re-plated, and counted 7 or 10 
days later, day 21 for U87NS and U118NS and day 30 for 5075 and GS8-26 
lines , to determine secondary sphere formation capability. 
Western blotting 
Cells were lysed in RIPA Buffer (Boston BioProducts #BP-115), supplemented 
with protease inhibitor cocktail tablets (Roche, complete mini, #11 836 153 001), 
and 5mM NaF. Protein was quantified via Bio-RAD Protein Assay Dye Reagent 
Concentrate (BIO-RAD, #500-0006) on the Beckman Coulter DU640 
Spectrophotometer. Proteins were separated by PAGE and electo-transferred to 
PVDF membranes (Pall Corporation, BioTrace PVDF 0.45um, P/N 66543). 
Membranes were blocked in 5% milk tris-buffered saline with tween 20 (0.1%; 
TBS-T). Primary antibodies were incubated overnight on a rocker in 5% bovine 
serum albumin in TBS-T at 1:1000 at 4°C.  Membranes were washed the 
following day 3x, 5’, TBS-T, and incubated with either mouse or rabbit 
horseradish peroxidase secondary (Cell Signaling #7076S and #7074) for 2 
hours room temperature. Proteins were detected via film following the Thermo 
Scientific’s SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher 
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Scientific, #34087) or Thermo Scientific’s SuperSignal West Femto Maximum 
Sensitivity Substrate (#34095) protocol. The following antibodies were purchased 
from Cell Signaling Technology:  B-Actin (#3700), BiP (#3177), CHOP (#2895), 
ATF-4 (#11815), Rad51 (#8875), Phospho-Histone H2A.X (#2577), H2A.X 
(#2595), ATM (#2873), Phospho-ATM (#13050), CHK2 (#6334), Phospho-Chk2 
(#2661).  
Trypan blue positive and negative counts 
U87NS cells were pH dissociated, filtered, and plated at 250,000/10mL in T75 
flasks. Cells were treated with DMSO, JLK1486, TMZ, or TMZ+JLK1486. On day 
7 cells were given fresh media and dosed a second time with JLK1486. On day 
14 cells were pH dissociated and re-plated at 172,000/10mL in T75 flasks. Cells 
were pH dissociated and positive and negative trypan blue cells (GIBCO, Trypan 
Blue Stain 0.4%, #15250) were counted.  
FACS analysis 
Drug treated U87NS were pH dissociated, filtered, washed 3X in PBS, and fixed 
in 95% ethanol overnight at 4°C. Propidium iodide versus Annexin V staining was 
performed by the UMASS FACS Core, and samples were run on the Calibur 
FACS machine. Analysis was completed using Flow Jo 7.6.    
shRNA ATF4 
pGIPZ shATF4 C1 (OligoID: V2LHS_132755), shATF4 E7 (OilgoID: 
VDLHS_132757), and sh Control were purchased from the UMASS RNAi Core 
Facility. U87MG cells were infected according to the UMASS RNAi Core Facility 
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Protocol. Briefly, 1x105 cells/well were plated, infected 24 hours later with viral 
supernatant and 1 $g/$l polybrene (Millipore, TR-1003-G), media changed 24 
hours post infection and cells were selected for seven days in 2 $g/mL puromycin 
(GIBCO, #A11138-03). Infected U87MG cells were then converted to U87NS 
cells as described above. 
Ethics Statement 
Investigation has been conducted in accordance with the ethical standards and 
according to the Declaration of Helsinki and according to national and 
international guidelines and has been approved by the author’s institutional 
review board. 
Mouse xenograft models 
Six-week old male NU/NU mice were purchased from Charles River Laboratories 
and injected with 1x106 U87NS cells in 100uL PBS/ right flank. When tumor 
volumes reached 150mm3 mice were dosed intraperitoneal (IP) with either 
DMSO (day 0, day3, day 6, day 9), JLK1486 15mg/kg (day 0, day 7), TMZ 
5mg/kg (day 0, day 7) or with the following dosing regimen: TMZ 5mg/kg (day 0), 
JLK 1486 15mg/kg (day 3), TMZ 5mg/kg (day 6), JLK1486 15mg/kg (day 9). Mice 
were sacrificed when tumors reached 1200mm3. 
H2A.X Immunofluoresence Staining 
U87NS cells were adhered to slides using Double Cytofunnel Disposable 
Chambers (Thermo Scientific, #5991039), fixed in 4% PFA/PBS (10 minutes), 
permeabilized in 0.5% TRITON X/ PBS (5 minutes), blocked in normal goat 
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serum (1 hour), stained overnight with either phospho-histone H2A.X (Ser139) 
(Cell Signaling, #2577) or rabbit (DA1E) mAb IgG XP isotype control (Cell 
Signaling, #3900), washed in 1X PBS, incubated with goat anti-rabbit IgG  (H+L) 
secondary antibody, Alexa Fluor 568 (Life Technologies, #A-11011), and 
mounted via ProLong Gold Antifade Mountant with DAPI (Molecular Probes by 
Life Technologies, #P36941). Images were acquired with a Leica wide field 
scope microscope. 
Statistical analysis in vitro 
The t-test analysis was performed using GraphPad Prism version 6.00 for Mac, 
GraphPad Software, La Jolla California, USA, www.graphpad.com 
Statistical analysis in vivo 
Kaplan-Meier time to tumor volume doubling curves were analyzed via the log-
rank test. 
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CHAPTER III 
Discussion overview 
Glioblastoma multiforme tumors are comprised of genetically 
heterogeneous cells [1-3] [4]. This results in highly proliferative, therapy-resistant, 
and infiltrative tumors with limited treatment options [1].  The current standard of 
care, which has not changed in over a decade, is comprised of surgical resection 
followed by radiation with concomitant and adjuvant temozolomide [1] [5]. 
Despite treatment, patients relapse within 6.9 months of completing therapy and 
have an overall survival of only 12-14 months [5].  This leaves much room to 
improve the standard of care and tackle unanswered questions regarding 
resistance, recurrence, and the cell of origin. Answering these difficult questions 
may facilitate the development of better-targeted therapies. 
Triad failure: caveats of surgical resection, radiation, and temozolomide 
Caveats of surgical resection 
Surgical resection is limited by two factors. First, tumor location 
determines whether or not resection is feasible [161].  Second, because GBMs 
are highly infiltrative, complete surgical resection is nearly impossible [1] [23]. 
This leaves a population of glioma cells at or near the primary tumor bed that 
contribute to nearly 90% tumor recurrence at the initial site [1] [21]. Although 
residual tumorigenic cells are a likely source of recurrence, it does not explain 
how they remain viable and re-populate the tumor bed following multiple rounds 
of radiation and chemotherapy. 
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Caveats of radiation: tolerance, increased DNA repair, proliferation  
Although the addition of radiation to surgical debulking increased overall 
survival from 3-4 months to 7-12.1 months, radiation is limited by neurological 
toxicity to normal brain tissue [5] [47, 162]. Patients receive focal fractionated 
doses over a 6-week time course, 2 Gy per day for five days, resulting in a total 
of 60 Gy [5]. As radiation does not prevent tumor recurrence, it is important to 
understand how cells remain viable despite multiple insults.  
In order for radiation to be effective, it must create DNA lesions either 
through direct ionization or through the formation of free radicals [69]. These 
lesions include base damage, single strand breaks, and double strand breaks. 
Mammalian cells dosed with 1-2 Gy have over 1,000 damaged bases, 1,000 
single strand breaks (SSBs), and 40 double strand breaks (DSBs) [69].  
Damaged bases accounting for the highest number of lesions generated by 
radiation are easily repaired by either nucleotide excision repair (NER) or base 
excision repair (BER) [69]. Similarly, SSBs are not lethal if they are repaired by 
the BER enzyme, poly(ADP) ribose polymerase (PARP) [69]. However, if SSBs 
are not repaired, they generate DSBs during a second round of replication, 
resulting in a G2/M arrest [69]. If DSBs are not repaired by either homologous 
recombination (HR) or non-homologous end joining (NHEJ) during the arrest, the 
cell undergoes apoptosis.  Damaged bases and SSBs DNA lesions occur at a 
25:1 ratio in comparison to DSBs [69] [74]. As the majority of accrued lesions 
from RT result in repairable SSBs and damaged bases, it becomes clear how 
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cells can survive multiple rounds of therapy. If SSBs are converted into DSBs, or 
DSBs arise from RT, gliomas circumvent their lethality by increasing expression 
of DNA DSB repair factors, in particular RAD51 [16] [59]. This limits the formation 
of catastrophic DNA DSBs, reducing cell death. The types of DNA damage 
coupled with increased DNA repair explains, in part, how cells remain viable 
following RT. 
Two additional factors must also be considered when assessing glioma 
cells response to RT. In order for RT to be effective, cells must be replicating. As 
previously discussed, GBMs are highly proliferative due to mutations in receptor 
tyrosine kinase pathways resulting in loss of cell cycle control [1] [4] [25]. This 
should increase GBM tumor cells’ sensitivity to radiation; however, isolation of 
slow-cycling cells with cancer stem cell like properties and increased resistance 
to RT have been isolated [163, 164]. These cells likely contribute to recurrence. 
Lastly, the formation of ROS are dependent on the presence of oxygen. As 
GBMs are solid tumors with an aberrant vasculature causing moderate to severe 
levels of hypoxia, this may limit ROS formation, increasing glioma cell viability [9] 
[46,47] [69]. Although the addition of RT to surgery significantly increased patient 
survival, its limitations eventually result in resistance and recurrence, through 
increased expression of DNA repair factors, slow cycling cells, and hypoxia.  
Caveats of temozolomide: MGMT, MMR, P53, proliferation 
In 2005 Stupp et al published their landmark study showing that addition 
of the DNA alkylating drug, temozolomide (TMZ) to RT significantly increased 
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survival from 7-12.1 months to 14.6 months [5]. Although this combination 
significantly improves overall survival, it is unable to prevent tumor recurrence 
[34] [162]. As TMZ’s mechanism has been delineated, caveats leading to its 
resistance have been identified.  
TMZ, a pro-drug stable at acidic pH, crosses the blood brain barrier, is 
hydrolyzed to form the reactive intermediate MTIC, which breaks down to a DNA-
alkylating methyldiazonium ion [29, 30]. This results in alkylation of guanine N7 
(70%), adenine N3 (9.2%), and guanine O6 residues (5%) [29] .  Because DNA 
glycosylases and BER recognize and remove the alkyl groups on guanine N7 
and adenine N3 residues, these adducts are not considered deleterious [29] 
[165]. However, neither DNA glycosylases nor BER are capable of removing 
guanine O6 adducts, resulting in stable adduct formation [29].  During replication, 
the alkylated guanine is paired with a thymine. This activates the mismatch repair 
pathway (MMR) [29] [31]. However, due to changes in its shape, the only base 
that can pair with an alkylated guanine is thymine, causing repeated insertion 
and excision of the thymine. This results in futile rounds of MMR and generates a 
single strand break as the polymerase skips over the alkylated base. The single 
strand break, if not repaired, is converted to a catastrophic double strand break 
during a second round of replication, eventually triggering apoptosis [32, 33].   
The first caveat to TMZ treatment is expression of methyl guanine methyl 
transferase (MGMT) [1]. MGMT recognizes O6 alkylated guanine residues and 
catalyzes the transfer of the alkyl from the guanine to its internal cysteine residue 
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[32]. This restores DNA base integrity, preventing formation of SSB and DSBs 
[166]. Forty five percent of GBM patients present with methylated MGMT 
promoters, leading to a two-year survival rate of 46% compared to a dismal 
13.8% two-year survival of patients with non-methylated MGMT promoter [1]. A 
similar trend is observed in vitro. Over-expression of MGMT in MGMT negative 
lines reduces cell death by 90% in response to TMZ, highlighting how vital this 
enzyme is in promoting TMZ resistance [33]. Accordingly, only 5.4% of recurrent 
GBM patients respond to TMZ [1]. This leads one to think that MGMT positive 
cells serve as a reservoir of resistant cells during TMZ treatment and lead to 
tumor repopulation when treatment is completed. This also raises the possibility 
that radiation and chemotherapy leads to the selection of a population of 
resistant cells, resulting in a cohort of highly malignant cells upon treatment 
completion.  
TMZ’s efficacy is dependent on MMR detection of alkylated guanines 
paired with thymines.  If MMR proteins are mutated, the cell is unable to 
recognize the guanine-thymine pairing and does not undergo futile rounds of 
MMR resulting in SSBs and DSBs [62] [167].  Instead of initiating apoptosis, 
inactivated MMR leads to A:T transitions [32]. Depending on where the point 
mutations occurs, this may promote tumorigenicity by inactivating tumor 
suppressor genes. Several studies have implicated loss of MMR factors, MSH6 
and MSH2, with increased resistance to TMZ [32] [168-170]. This is especially 
true of recurrent GBM tumors in which MSH6 deficiency correlates with 
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increased growth during treatment [169] [171]. This highlights the second caveat 
in which TMZ treatment eradicates MGMT negative and MMR intact cells, 
leaving resistant MGMT positive and/or MMR negative cells to repopulate the 
tumor bed. 
In addition to MGMT and MSH6 status, efficacy is dependent on three 
additional factors: RAD51, P53, and proliferation. Even if GBM cells have an 
intact MMR system that generates DSBs, glioma cells evade death by increasing 
expression of RAD51, a DNA repair factor that facilitates homologous 
recombination [62]. Increased RAD51 expression decreases catastrophic DNA 
DSBs, promoting viability and resistance to TMZ.   
P53 mutant glioma cells are significantly more viable and undergo less 
death than P53 wild type cells in response to TMZ treatment [33] [171]. TMZ 
induces DNA DSBs, activating the DNA damage response kinase ATM [172]. 
ATM activates P53, increasing transcription and activation of FAS receptor 
mediated apoptosis [33] [50] [173].  P53 mutant cells do not increase FAS 
transcription in response to TMZ, accounting for the observed decrease in cell 
death. However, decreased levels of the anti-apoptotic Bcl-2 protein and 
activation of mitochondrial caspases (Csp9, Csp3) are detected in TMZ treated 
P53 mutant cells [33].  Although mitochondrial apoptosis does result in a small 
percent of cell death, it is significantly less than P53 wild type cells, suggesting 
TMZ induced apoptosis is dependent on P53 [33]. As the majority of de novo 
GBMs are P53 wild type, the cells should be sensitive to TMZ treatment [173]. 
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Conversely, 65% of secondary GBMs present with P53 mutations [20] [33].  This 
severely limits TMZ efficacy, resulting in maintenance of a viable population of 
P53 mutant cells. As radiation also relies on P53 induced apoptosis, these cells 
may exhibit dual resistance.  
Lastly, TMZ is only efficacious in proliferating cells [29] [32]. If a cell is in 
G0 or has already exited M phase when a guanine residue undergoes O6 
alkylation, generation of deleterious DNA DSBs do not occur. If cancer stem-like 
cells have a slower propagation cycle , this would also prevent them from 
undergoing cell death in response to TMZ. Therefore, non-proliferating cells may 
lead to recurrence. 
Radiation and temozolomide efficacy is limited by delivery, tolerance, the 
type of DNA damage, as well as MGMT expression, MMR and P53 status, and 
proliferation.  Although these factors contribute to the development of a 
population of resistant cells capable of re-populating the tumor bed, leading to 
the inevitable tumor recurrence, recent data suggests cancer stem like cells also 
contribute to resistance and tumor recurrence. 
The cell of origin: glioma cancer stem cells versus astrocyte de-
differentiation  
Glioma cancer stem cells 
 A small percentage of cells from acute myeloid leukemia patients can 
recapitulate the parental disease when transplanted into immunodeficient mice 
[174, 175]. This finding led to the cancer stem cell (CSC) hypothesis that a sub-
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population of cells within tumors mimics normal stem cell properties of self-
renewal and differentiation, but acquire mutations that lead to the development 
and maintenance of heterogeneous tumors [176, 177]. The identification of a 
population of neural stem cells (NSCs) in the subventricular zone (SVZ) of adult 
brains capable of differentiating into astrocytes, oligodendrocytes, and neurons, 
while maintaining properties of self-renewal, gave basis for the glioma cancer 
stem cell hypothesis [178-181].  In 2003, Singh et al isolated a population of 
CD133+ cells from brain tumors with self-renewal and proliferating properties that 
could differentiate into tumor cells that phenotypically mimicked the patient’s 
tumor [164].  Further study showed intracranial implantation of CD133+ cells gave 
rise to tumors that can be serially transplanted while maintaining the parental 
phenotype [164, 165].  As CD133- cells did not maintain stem cell properties and 
were unable to form tumors when implanted, it was suggested that CD133+ cells 
were a population of cancer stem cells capable of initiating brain tumors [164, 
165].  Characterization of these cells showed increased resistance to both 
radiation and temozolomide in comparison to CD133- due to activation of CHK1 
and CHK2 DNA damage pathways and expression of ABCG2 transports, which 
export chemotherapies from the cell [24] [182, 183]. A population of therapeutic 
resistant brain CSCs capable of maintaining their oncogenic potential due to self-
renewal properties provides an attractive alternative source accounting for GBM 
recurrence.   
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Although evidence suggests CD133+ brain tumor CSCs contribute to GBM 
development, much controversy and skepticism surrounds this theory.  Later 
studies suggested that CD133- cells can also be maintained in an 
undifferentiated state in vitro, are capable of self-renewal, and when implanted 
can give rise to tumors [24] [184-187]. This clearly calls to question the use of 
CD133 as a marker for identifying brain cancer stem cells. Indeed, this marker 
has been shown to be quite promiscuous, as it also labels epithelial cells in the 
liver, kidney, and pancreas, suggesting CD133 expression is not specifically 
limited to neural stem cell populations [188, 189].  Further complicating the 
matter, different dissociation methods result in different percentages of CSCs 
from tissue, and different CD133 antibodies detect alternative glycosylation 
patterns, resulting in different isolation efficiencies [190].  Currently, several new 
markers, such as CD44, CD15, and integrin 2 and 6, are being explored as 
potential candidates for brain CSCs [24]. However, until a specific marker 
validated for brain tumor cancer stem cells is identified, it is doubtful this debate 
will be resolved.  
Two points should be kept in mind before dismissing the brain cancer 
stem cell hypothesis. First, the identification of cancer stem cells from several 
other solid tumors, including breast, colon, pancreas, lung, and skin, provides a 
foundation for cancer stem cells in solid tumors [24] [190]. Second, orthotopically 
transplanted  P16INK4a P19ARF deficient neural stem cells transduced with EGFR 
gave rise to high grade gliomas, showing that loss of tumor suppressor genes 
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(TSGs) and activation of receptor kinases are capable of transforming NSCs 
[191, 192].  Similarly, ablation of PTEN, P53 and RB TSGs in stem cells isolated 
from the SVZ gave rise to gliomas [193]. This suggests it is possible for stem 
cells within the SVZ to lose TSGs, resulting in tumorigenic cells that give rise to 
GBMs. How CSCs gain these mutations is under investigation. As stem cells are 
closely associated with endothelial cells, their interactions with the vasculature 
may prevent differentiation and maintain the capacity for self-renewal while 
releasing cytokine that increase their proliferation [184]. Recent studies suggest 
aberrancies within this delicately balanced NSC niche may contribute to CSC 
development, but until further studies are completed, this remains to be seen 
[184] [194].  
The proposed brain cancer stem cell suggests why these tumors are so 
difficult to treat and impossible to eradicate. A population of cancer cells with 
stem like properties would create a pool of cells with unlimited ability to re-
populate the tumor. This would contribute not only to initial tumor development 
but also to tumor recurrence.  It would then be critical to develop therapies that 
not only target the bulk of tumor cells, but also cancer stem cells. If specific 
markers for brain cancer stem cell can be identified, perhaps these can be 
manipulated and exploited by nano particle or viral mediated delivery of 
chemotherapies.  
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Astrocyte de-differentiation  
Excluding astrocytes, the adult brain is mainly comprised of non-
proliferating cells [24]. Because of this, it was suggested that GBMs result from 
loss of tumor suppressors and activation of oncogenes in astrocytes [24]. This 
traditional view suggests that these mutations trigger de-differentiation, increase 
proliferation, and generate tumorgenic astrocyte like cells.  This would account 
for GBMs genetic and morphological heterogeneity. 
The finding that adult fibroblasts can de-differentiate into induced 
pluripotent stem cell (iPSC) state by re-expression of stem cell transcription 
factors (OCT3/4, SOX2) gave merit to this argument [195, 196]. Further 
substantiating this, c-myc transformed iPSCs gave rise to subcutaneous tumors 
in mice, suggesting that de-differentiated cells are tumorigenic [196]. Building on 
this premise, astrocytes de-differentiate in response to loss of P16INK4a and 
P19ARF plus EGFR activation [192, 193 ]. This produced a transformed 
population of cells that gave rise to tumors that phenotypically matched high-
grade gliomas.   
Although this data suggests transformed astrocytes give rise to GBMs, 
whether or not a transformed astrocyte is the cell of origin has not been 
conclusively resolved in the field for two reasons. First, studies show that 
knockouts of PTEN, P53, and RB TSGs are unable to transform normal human 
astrocytes [194] [197]. This is surprising as P53 mutations occur in almost 65% 
of progressive GBMs and PTEN mutations have been reported as high as 63% in 
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de novo GBMs [20] [32]. One would expect that loss of these TSGs would result 
in transformation if astrocytes are indeed the cell of origin However, it is possible 
that lack of EGFR amplification or expression of the VIII variant, hallmarks of 
GBMs, could account for this non-transformed state [4] [21]. Experiments in 
which EGFR amplification/VIII expression in combination with loss of TSGs in 
astrocytes would help to resolve this question. Second, the marker used by many 
to isolate and identify astrocytes, GFAP, is also expressed on neural stem cells 
[24]. It is possible that astrocyte cultures were cross-contaminated with NSCs 
and resulting tumor formation was due to transformed NSCs, not transformed 
astrocytes.  
The GBM cell of origin remains a contested subject. As attractive as brain 
cancer stem cells are to promoting GBM development, resistance, and 
recurrence, the use of controversial markers makes it difficult to isolate these 
cells and validate their roles.  De-differentiation of astrocytes would account for 
the typical astrocytic phenotype and genetic heterogeneity of GBMs, but there is 
a debate whether these cells are maintained within the tumor and generate 
recurrences.  As GBMs are comprised of heterogeneous populations of cells that 
are genetically aberrant, it is impossible to exclude one cell of origin from 
another. It is plausible that GBMs result from both de-differentiated astrocytes 
and cancer neural stem cells.  Studies seeking to resolve this debate are 
complicated as many do not differentiate between de novo and progressive 
GBMs, while the dissociation protocol and culture condition vary, and the lack of 
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markers make it difficult for experiments to be reproduced. What does remain is 
that GBMs are aggressive grade IV brain tumors with limited treatment options 
that have not substantially changed in over a decade. Understanding the 
limitations of combination therapies and why they have not improved patient 
survival may lead to the design and development of smarter drug combinations. 
Combination therapies: harnessing failures to improve drug combinations 
MGMT inhibition 
 As MGMT expression promotes TMZ resistance, it was reasoned that its 
depletion could re-sensitive TMZ resistant lines. This was shown to be quite 
effective in vitro as treatment of MGMT positive cells with O6 benzylguanine (O6-
BG) successfully inactivated MGMT due to transfer of a benzyl group to the 
cysteine residue essential for removal of alkyl groups [198-200].  This resulted in 
increased sensitivity to TMZ. This finding led to a phase I trial that explored the 
addition of O6-BG to TMZ treatment [201]. Although O6-BG effectively inhibited 
MGMT expression in patients’ tumors, the combination induced severe 
myelosuppresion, limiting its clinical use [202].  Currently, the infusion of 
hematopoietic progenitor cells (HPCs) modified to express high levels of MGMT 
via retroviral vectors is being explored in animal models [168]. However, this has 
yet to be implemented in a clinical setting for GBM patients.  
 A second approach is to deplete MGMT levels with higher doses of TMZ 
over a longer time period. Because MGMT is a suicide enzyme, TMZ eventually 
depletes it [168]. This means that the cell must re-synthesize MGMT to replenish 
""(
its reservoir during and following TMZ treatment. A phase II study implementing a 
21 days on, 7 days off, TMZ treatment at 75-100mg/m2/day found the increased 
dose and duration to be safe, but only resulted in a 6 month progression free 
survival in 11% of patients, suggesting little advantage [168]. This could be due 
to cancer cells expressing increased DNA repair factors or mutations in MMR 
factors MSH2 or MSH6. 
An alternative approach is to use viral vectors to delivers siRNAs against 
MGMT. Initial in vitro and murine in vivo studies are promising [168]. This has not 
yet been pursued in the clinic as vector toxicity, specificity, and duration must first 
be analyzed in higher primates. 
Although MGMT inhibition resulting in re-sensitization to TMZ treatment 
has been achieved in vitro, this has not translated into clinical applications, 
leaving clinicians with the triad of resection, RT, and TMZ. 
BCNU wafers 
 As GBMs are infiltrative and complete surgical resection is nearly 
impossible, it was thought that implantation of biodegradable chemotherapeutic 
wafers at the surgical site would target remaining glioma cells, preventing or at 
least delaying recurrence. In 2002, the FDA approved the use of Gliadel wafers 
containing the nitrosourea drug carmustine [168]. Over a course of several 
weeks, the drug is slowly released from the wafers, promoting deleterious DNA 
interstrand crosslinks.  Despite direct wafer implantation, a phase III trial only 
increased median survival from 11.6 to 13.9 months [1].  Furthermore, addition of 
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Gliadel to TMZ and RT did not result in a statistically significant increase in 
overall survival in comparison to TMZ and RT [168]. This lackluster response 
was accompanied by edema and cerebrospinal fluid leakage. It is probable that 
glioma cells resolved Gliadel-induced crosslinks by NER and increased HR. The 
inability of BCNU wafers implanted at the primary tumor site to prevent 
recurrences highlights how difficult and challenging it is to find effective therapies 
for this cancer. 
Angiogenic inhibition: Bevacizumab 
 GBMs are highly vascularized solid tumors. However, the vasculature 
network in GBMs is often aberrant due to hyperplastic endothelial cells forming 
twisted vessels that are leaky, lack pericyte coverage and cell-cell adhesion, and 
form dead-end junctions instead of interconnecting loops [202]. In 2009, the FDA 
approved bevacizumab (BEV), a monoclonal antibody against vascular 
endothelial growth factor A (VEGFA), for use in recurrent GBM patients [168] 
[203]. It was suggested that inhibition of VEGFA would decrease activation of the 
VEGF receptor on hyperplastic endothelial cells, resulting in vessel trimming and 
normalization, increasing blood flow and delivery of chemotherapeutics [168] 
[204]. Combination studies of BEV with irinotecan were explored in GBM 
patients. Irinotecan, a topoisomerase I inhibitor, was chosen for two reasons. 
One because it had been previously shown to cross the BBB and two, 15% of 
recurrent GBM patients showed partial response to Irinotecan as a single agent 
[204]. Although combination therapy did increase the 6 month progression free 
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survival, the treatment increased tumor infiltration [1] [4] [168]. Analysis of tumor 
sections indicated larger areas of hypoxia leading to increased expression of 
matrix metalloprotease 2 and insulin binding protein 2 [168]. The same 
phenotype resulted when intracranial injection of non-invasive GBM cell line into 
mice treated with BEV for 4-6 weeks gave to rise to invasive tumors expressing 
increased hypoxia as well as up-regulated glycolysis genes and targets of HIF1 
alpha [168]. This suggests that BEV treatment is a double-edge sword in that it 
normalizes vasculature, increasing delivery of chemotherapies, but also 
increases invasion and metastasis. It is possible that combination of BEV with an 
agent other than irinotecan may prevent this phenotype; however, finding drugs 
capable of crossing the BBB greatly limits this.  An alternative option would be 
the use of an EGFR inhibitor, such as erlotinib or gefitinib, with BEV, as EGFR 
contributes to angiogenesis, proliferation and survival. This combination coupled 
with RT may increase efficacy.  Bevacizumab treatment is further limited as it 
only targets one of the five VEGF family members [204]. This allows other 
members to compensate for its depletion, maintaining the hyperproliferative state 
of endothelial cells within the vascular tumor niche, contributing to its decreased 
efficacy [168] [204]. 
Receptor tyrosine kinase inhibitors: erlotinib and gefitinib 
The epidermal growth factor receptor is an attractive target to inhibit as it 
is amplified in 50-63% of primary GBMs, promoting glioma cell proliferation and 
apoptotic resistance [1] [4] [20]. It was thought that the use of erlotinib or gefitinib, 
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two small molecule inhibitors against EGFR, would decrease proliferation and 
sensitize cells to radiation and chemotherapy [4]. However, clinical use of the 
compounds resulted in little to modest advantage. Two factors contributed to this. 
First, 50% of patients with EGFR amplification express the VIII variant, resulting 
in loss of the extracellular domain due to deletions of exons 2-7 [1].  Erlotinib 
competes with the ATP catalytic site found in EGFR’s intracellular domain [205]. 
Loss of the extracellular domain results in constitutive activation of the receptor, 
preventing the drugs from accessing EGFR’s ATP catalytic site. Second, GBM 
patients develop erlotinib resistance by increasing expression of the RAC1 
GTPase [206]. Increased RAC1 expression activates the MAPK and JNK 
pathways by an alternative mechanism, circumventing EGFR inhibition. In vitro 
studies show that combination of erlotinib with a RAC1 inhibitor decreases 
glioma cells viability and self-renewal [206]. In vivo studies show the combination 
decreases tumor volume and invasiveness, suggesting this combination may 
have clinical application and should be further explored [206]. This also suggests 
the best approach to glioma therapy is not single agents, but rather combination 
therapies targeting different biochemical pathways.   
Although inhibition of MGMT, implantation of BCNU wafers, and anti-
angiogenic and small molecules targeting EGFR are unable to prevent or 
increase time of tumor relapse, they do provide insight into how resistance is 
generated and mechanisms of treatment failure.  Understanding these caveats 
may lead to smarter drug combinations, as illustrated by RAC1 and erlotinib. 
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Towards this goal, the use of drugs that interfere with endoplasmic reticulum 
(ER) associated degradation and function are further explored in this discussion.  
Application and implementation of clinically approved drugs that disrupt 
ER function 
Overview 
 GBMs are solid tumors with moderate to severe levels of hypoxia [7] [9] 
[46, 47]. Their aberrant vasculature results in decreased delivery of nutrients, 
glucose, and removal of toxic metabolites [4].   As protein synthesis and folding is 
dependent on ER homeostasis, its disruption triggers the endoplasmic reticulum 
stress response, resulting in decreased mRNA translation and expression of 
factors to alleviate ER stress [10] [39]. If the stress is resolved, normal ER 
functioning resumes. However, if the cell is unable to do so, it undergoes ER 
mediated apoptosis [75]. As GBMs are in a chronic state of ER stress, they 
should be at high risk of this. To avoid this, GBMs increase expression of pro-
survival ER factors [11-15]. This is advantageous for two reasons. First, it 
decreases ER mediated apoptosis and, second, allows the synthesis of DNA 
repair and cell cycle proteins that glioma cells require for survival and 
proliferation. Two means of targeting this pathway have been suggested [10] 
[39]. First, it may be possible to push the ER past its capacity to function by 
treating cells with an ER stress-inducing drug. The second approach is to block 
ER associated degradation (ERAD) of proteins, preventing cells from clearing 
unfolded or misfolded proteins.  
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Bortezomib (Velcade) 
 Bortezomib prevents 26S proteosomal mediated degradation of unfolded 
or misfolded proteins by inhibiting its chymotrypsin property [206, 207]. In 2003, 
the FDA approved it for clinical use for multiple myeloma and mantle cell 
lymphoma [208]. As promising results ensued, trials in solid tumors followed 
[207]. This was based on in vitro studies suggesting bortezomib sensitizes non 
small cell lung cancer to radiation, increases apoptosis in glioma cell lines when 
combined with a histone deacetylase (HDAC) inhibitor or TMZ, and increases 
pancreatic and ovarian cancer cells sensitivity to the DNA crosslinking agent 
cisplatin [39] [45] [208] [209]. Additionally, the combination of bortezomib with RT 
or HDAC inhibitors decreases expression of DNA repair factors such as RAD51, 
BRAC1, and FANCD2 [44, 45] [210, 211]. This leads to decreased HR, making it 
an attractive drug candidate for GBM patients.  A phase I trial analyzing 
bortezomib efficacy in recurrent gliomas has been completed, but study results 
have yet to be posted (completed April 2016; NCT01435395).  There is a trial 
currently underway studying the combination of TMZ and radiation with 
bortezomib in GBM patients (NCT0099801). As the study has not been 
completed, no results are available. However, recent in vitro data of solid tumors 
responding to bortezomib suggest several limitations. First, solid tumor 
xenografts only had modest inhibitory growth effects with bortezomib due to 
delivery and penetration issues [207-209]. Second generation drugs are currently 
being developed using liposomal encapsulation to increase delivery; however, 
"#$
this does not solve penetration issues [45]. An in vivo lung cancer model 
correlated decreased bortezomib response to decreased perfusion [209]. This is 
especially problematic in GBMs as the aberrant vasculature impedes drug 
penetration.   
In addition to inhibiting proteasomal degradation, bortezomib also changes 
mitochondrial potential, triggering release of cytochrome C and activation of 
mitochondria mediated apoptosis [45]. It also inhibits the degradation of the 
NFkB inhibitor, decreasing transcription of downstream targets [45] [207, 208]. 
Although these additional mechanisms promote cell death, they may also 
increase the toxicity of the drug in vivo. Perhaps the most concerning side effect 
of bortezomib is data suggesting it induces proliferation of endothelial cells [208]. 
Taken together, it is understandable why many are skeptical and have concerns 
for the use of bortezomib in solid tumors. However, until the trial exploring 
bortezomib in combination with TMZ and radiation is completed, these concerns 
remain just that, concerns. 
Celecoxib 
 Celecoxib, a COX2 inhibitor, is a non-steroid anti-inflammatory drug 
(NSAID) originally developed for pain management [10]. It was approved for 
clinical use in 1998 but in 2002 was suggested to have potential anti-tumor 
properties as it has the unintended side effect of sarco endoplasmic reticulum 
ATPase (SERCA) pump inhibition [212, 213]. SERCA is one of two pumps in the 
ER that regulate calcium influx and efflux [84]. Disrupted calcium homeostasis, 
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results in ER calcium leakage triggering release of cytochrome C from 
mitochondria [84]. This was attractive as, one, this drug has FDA approval and, 
two, induction of cell death through perturbed ER function has been validated by 
extensive in vitro studies using tunicamycin and thapsigargin [10]. Additionally, 
celecoxib increases the pro-death ER stress transcription factor, CHOP [214]. 
Although celecoxib was suggested to increase cell death in tumor cells due to ER 
disruption, clinical trials have generated unimpressive responses [10]. Because 
SERCA inhibition is not celecoxib’s main function, development of celecoxib 
derivatives with increased SERCA inhibition is currently under investigation [10] 
[213] [215]. This may not only increase celecoxib’s SERCA inhibition but also 
leads to increased CHOP expression. A phase II study using celecoxib in 
combination with TMZ has been completed in GBM patients (NCT00112502).  
Although study results have not yet been published, it does add conceptual merit 
to the argument of why ER stress manipulation may be a relevant therapy in 
GBMs. 
Nelfinavir 
 The FDA approved nelfinavir, a HIV protease inhibitor, in 1997 for clinical 
use [10]. In addition to functioning as a protease inhibitor, it induces ER stress 
and activates the unfolded protein response (UPR) as well as induces autophagy 
and apoptosis [87]. The mechanism accounting for these multiple results is 
uncertain, but AKT inhibition has been suggested [216]. Nelfinavir treatment of in 
vivo GBM tumors leads to decreased tumor volume due to accumulation of 
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polyubiquinated proteins triggering ER stress and CHOP induction [214]. CHOP 
expression increased the transcription of death receptor 5 leading to TRAIL 
mediated apoptosis [87] [147] [214] . Because of these promising in vitro results 
and the FDA approval of nelfinavir, a phase I clinical trial was established to 
study the combination of nelfinavir with radiation and TMZ in GBMs 
(NCT01020292). As this study is currently ongoing, no data is available.  
 The use of ER stress inducing drugs in combination with TMZ and/or 
radiation in GBM patients sets the precedent for the use of combination therapy. 
The aforementioned kinase, anti-angiogenic, MGMT, and proteasome / ER 
stress inhibitors show little efficacy as single agents [44,45] [207] [211]. It is not 
until they are used in combination with either TMZ or radiation that a robust effect 
is observed. Targeting two different pathways that gliomas rely on is more 
effective than targeting a single amplified or over-expressed signaling cascade.  
Although proteasome / ER stress inducing agents such as bortezomib, celecoxib, 
and nelfinavir are under clinical investigation, none of these agents specifically 
interferes with protein folding, directly inducing ER stress. Rather, their effects 
are either through proteasome inhibition or unintentional ER side effects. 
JLK1486 is mechanistically unique as it induces ER stress by alkylating thiol 
residues, preventing the formation of disulfide bonds, resulting in the 
accumulation of unfolded proteins [35, 36]. We reasoned that the inability to 
resolve ER stress would increase cell death caused by TMZ-induced DNA 
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damage. To explore this, we studied the in vitro and in vivo effects of 
TMZ+JLK1486 combination therapy. 
TMZ+JLK1486 combination therapy 
Overview 
Treatment of GBM non-adherent and primary lines cells with 
TMZ+JLK1486 reduced secondary sphere formation and in the case of U87NS 
cells, completely blocked secondary sphere formation, suggesting this 
combination effectively inhibits tumor cells from re-populating their culture. This is 
an important finding as GBM therapies fail due to prevent tumor recurrence. The 
mechanism of secondary sphere inhibition in U87NS cells is increased cell death.  
Interestingly, this effect was maintained over an extended time course, 
suggesting that this combination provides a durable effect. Furthermore, we 
found that treatment of subcutaneous tumors in mice with TMZ+JLK1486 
significantly delayed tumor doubling, suggesting the potential use of this 
combination in a clinical setting.  We propose two interconnected models by 
which TMZ+JLK1486 promotes cell death.  First, we suggest that prolonged, 
unresolved ER stress drives apoptosis through CHOP, and, second, the 
accumulation of unrepaired, deleterious DNA double strand breaks triggers 
apoptosis due decreased expression of the DNA DSB repair factor, RAD51. 
TMZ+JLK1486 induces prolonged, unresolved ER stress 
To understand the mechanism driving the enhanced efficacy observed 
with TMZ+JLK1486, we delineated the effects that this combination exerted on 
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the ER stress response pathway, with particular attention to levels of ATF4 and 
CHOP induction. It is well established that GBM cells are reliant upon the ER 
stress pathway and that overwhelming the ER stress pathway switches the initial 
pro-survival response to pro-death. JLK1486 is a viable candidate for this as it 
suppresses the formation of disulfide bonds that are essential for protein folding 
and functionality.  Indeed, when U87NS cells are treated with JLK1486 we see 
induction of ATF4 and its downstream target, CHOP, in JLK1486-treated cells, 
not TMZ- treated cells. This validates our hypothesis that JLK1486 and TMZ 
target different pathways and provides an explanation for why this dual treatment 
provides a robust response.  
We found our initial drug regimen, (Figure 5C) utilizing only one dose (1X) 
of JLK1486 at day 0 in combination with TMZ did not result in U87NS secondary 
sphere inhibition (Figure 6B). However, when we added a second dose (2X) of 
JLK1486 at day 7, we observed complete inhibition of U87NS secondary sphere 
formation (Figure 5D; Figure 6C).  It is plausible the second dose of JLK1486 at 
day 7 enhances inhibition of sphere formation by maintaining increased ATF4 
levels that contribute to a sustained and unresolved ER stress response. The 
expression levels of ATF4 correlate with increased expression of its downstream 
target, CHOP, consistent with this model. Increased levels of CHOP, a driver of 
apoptosis, are not observed until after the second dose of JLK1486 on day 7, 
again suggesting the second dose of JLK1486 prolongs ER stress levels and 
forces the pro-survival to pro-apoptotic switch that enhances cell death and 
"#)
reduces secondary sphere formation (Figure 6C; Figure 7; Figure 8).  Sustained 
ATF4 and CHOP expression in TMZ+JLK1486-treated cells correlates with our 
trypan blue positive time course, which shows increased cell death post day 14 
(Figure 7C-D). This suggests a model in which TMZ+JLK1486 treatment initiates, 
maintains, and promotes unresolved ER stress that drives apoptosis.  
TMZ+JLK1486 treatment generates and sustains DNA DSBs 
TMZ treatment results in the formation of DNA DSBs. If these breaks are 
not repaired, cells undergo apoptosis. Both TMZ alone and TMZ+JLK1486-
treated samples show DNA damage at early and late time-points; however, 
TMZ+JLK1486-treated samples exhibit stronger activation at later time points 
(Figure 9), suggesting prolonged DNA damage.  Although both TMZ alone and 
TMZ+JLK1486 samples exhibit markers for unresolved DNA DSBs, only TMZ-
treated cells have increased expression of RAD51, a key protein required for 
repair of DSBs.  RAD51-mediated repair of DSBs would lead to cell survival and 
proliferation.  We find this to be true in our TMZ alone treated cells where trypan 
blue positive counts decrease and trypan blue negative counts increase over 
time (Figure 7). Conversely, the decreased levels of RAD51 observed in 
TMZ+JLK1486-treated cells would lead to accumulation of unresolved DNA 
DSBs, prolonged !H2A.X induction and increased cell death. This pattern is 
exhibited in TMZ+JLK1486-treated samples where RAD51 levels are 
substantially lower than TMZ alone treated samples, correlating with increased 
DNA DSBs (Figure 9; Figure 10). Accumulation of unresolved DSBs due to 
"#*
decreased RAD51 levels is a plausible second mechanism for why 
TMZ+JLK1486-treated cells are unable to re-populate and instead initiate 
apoptosis (Figure 7H; Figure 9; Figure 14).  
Summary and Future Direction 
As we suggest two possible mechanisms for induction of cell death in 
TMZ+JLK1486-treated cells, one due to prolonged ER stress and the second due 
to unresolved DNA DSBs, we asked if a link between ER stress induction and 
RAD51 protein reduction could be found. When ATF4 is strongly expressed in 
JLK1486 and TMZ+JLK1486-treated samples, we observe reduction of RAD51 
protein  (Figure 8; Figure 9; Figure 11F). Conversely, when ATF4 levels 
decrease over time, as in day 23 samples (Figure 8) or are reduced via shRNA 
(Figure 11), RAD51 increases (Figure 8; Figure 9; Figure 11F). As ATF4 
knockdown increases RAD51 protein, it suggests that repression of RAD51 is 
dependent on ATF4 itself or an ATF4-regulated downstream pathway. This is 
intriguing as induction of ATF4 seems to greatly reduce RAD51 expression, but 
not other DNA repair factors, such as ATM and CHK2, to the same extent. This 
suggests a potential novel inverse relationship where ER stress leads to ATF4 
induction, resulting in decreased RAD51 protein (Figure 14). 
One can envision several possibilities for ATF4 regulation of RAD51 
expression. As ATF4 is a transcription factor, it is possible that it directly binds to 
the RAD51 promoter and represses RAD51 transcription through recognition of 
CRE-like sequences.  This is quite plausible as, addressed in the Introduction, 
"$+
ATF4 can act as either an activator or repressor depending on its binding 
partners.  ATF4 may block enhancers’ access to or prevent scaffolding at CREB-
like sequences promoting transcription.  Alternatively, ATF4 may either decrease 
the expression of RAD51 enhancers or increase expression of repressors. This 
would provide ATF4 with a repressor-binding partner. Both of these would 
account for decreased RAD51 transcription resulting in decreased protein 
observed in TMZ+JLK1486 treated cells.  Additionally, ATF4 may not effect 
RAD51 transcription but rather its translation. Perhaps ATF4 induction results in 
expression of a miRNA that increases RAD51 transcript degradation or prevents 
translation. This would also account for ATF4 induction leading to decreased 
RAD51 protein.  
ATF4 may indirectly negatively regulate RAD51 expression through 
increased CHOP expression. CHOP, a member of the C/EBP family, may bind to 
and repress RAD51 expression in response to sustained ATF4 protein levels. It 
may also bind to and sequester RAD51 activating or enhancer factors, 
preventing them from interacting with RAD51’s promoter. Either way, decreased 
RAD51 transcription leading to decreased protein levels would result.  
Alternatively, decreased RAD51 protein may occur due to decreased 
protein translation.  ER stress leads to phosphorylation of eIF2 alpha, decreasing 
translation of cap dependent mRNAs. If RAD51 is a cap dependent mRNA, then 
this could account for its decreased protein during sustained ER stress.  This 
would also be an alternative way to decrease MGMT levels in MGMT positive 
"$"
cells. As U87 cells are MGMT negative this could not be analyzed. However, a 
recent paper published by Xipell et al does show that ER stress induction 
correlates with not only decreased RAD51 protein levels but also MGMT levels 
[217].  As the effects of TMZ+JLK1486 treatment, ATF4 induction and decreased 
RAD51 protein, is sustained over a periods of 21 days, it suggests that this 
combination may be a durable means of decreasing MGMT in vivo. 
Although TMZ+JLK1486 prolongs ER stress resulting in unresolved DNA 
DSBs and apoptosis, it is unknown if this is indeed the result of decreased 
RAD51 protein levels. Over-expression of RAD51 in TMZ+JLK1486 treated cells 
may rescue the phenotype, validating the hypothesis that reduction of RAD51 is 
the mechanism of cell death in TMZ+JLK1486 treated cells.  It would also be 
interesting to explore this combination utilizing an intracranial mouse model in 
combination with radiation. This would give relevance to the potential clinical use 
of the treatment. 
Although the combination of TMZ+JLK1486 resulted in robust in vitro 
growth suppression and increased cell death, the in vivo use of the drug was 
limited by solubility and toxicity. We were able to circumvent solubility by 
administering the drug in low volumes (<50µL) of dimethyl sulfoxide; however, 
we were unable to dose above 15mg/kg 2X because of substantial body weight 
loss (Figure 13). The Kraus Laboratory has synthesized new analogues of the 
JLK1486 drug and suggests these analogues are as potent in vitro but have 
reduced toxicity. Due to time restraints, we were unable to test these new 
"$#
analogues in either of our in vitro or in vivo models; however, if these analogues 
do have decreased toxicity, then clinical application is much more feasible. 
Additionally, the Kraus Laboratory has recently encapsulated JLK1486 in 
nanoparticles, providing an alternative form of the drug that may lessen the drugs 
toxic side-effects. This may allow for increased dosing of the drug at higher 
concentrations and, when combined with TMZ, may provide a more durable and 
efficacious response in vivo.    
At this time, the best available therapy for GBM patients is comprised of 
surgical resection, radiation, and temozolomide [1] [5]. Clinical trials exploring the 
standard of care in combination with small molecular inhibitors will, hopefully, 
lead to an improved standard of care.  Perhaps this improvement will not come 
from small molecules but rather gene therapy.  A phase III study exploring the 
effects of an adenoviral vector expressing the herpes simplex virus type 1 
thymidine kinase (AdvHSV-tk) in combination with the standard of care found that 
addition of AdHSV-tk increased overall survival by 45 days [218]. As the 45 days 
was not found to be significant, the trial did not translate into clinical use [218]. 
However, this trial was conducted in 2005, the same year Stupp et al published 
their groundbreaking TMZ study.  Due to approval and accessibility issues, not all 
patients across the 38 different European clinics received the same treatment or 
regimen [218, [219]. This discrepancy clearly influences overall survival and as a 
result has led to the preparation of a glioma based AdvHSV-tk phase III in the 
United States [219]. 
"$$
Until gene therapy and personalized medicine become achievable clinical 
therapy options for GBM patients, the best approach is the exploration, use, and 
implementation of combination therapies. To this end, we suggest that 
TMZ+JLK1486 is an effective novel drug combination that results in cell death of 
U87NS cells due to the combination of prolonged ER stress induction and 
unresolved DNA damage through reduced RAD51. 
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